Stimulation	O
of	O
CD40	B-protein
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocyte	I-cell_type
-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	B-protein
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	B-protein
surface	O
expression	O
is	O
down-regulated	O
during	O
tumor	O
progression	O
.	O

CD40	B-protein
expression	O
was	O
confirmed	O
in	O
7	O
human	B-cell_line
MM	I-cell_line
cell	I-cell_line
lines	I-cell_line
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
advanced	O
stages	O
were	O
CD40	B-protein
negative	O
.	O

CD40	B-protein
expression	O
could	O
be	O
enhanced	O
in	O
CD40	B-protein
-positive	O
MM	O
by	O
stimulation	O
with	O
IFN-gamma	B-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
but	O
not	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1beta	I-protein
or	O
CD40	B-protein
triggering	O
.	O

CD40	B-protein
ligation	O
on	O
MM	O
by	O
CD40L-transfected	B-cell_line
murine	I-cell_line
L-cells	I-cell_line
or	O
by	O
a	O
soluble	O
CD40L	B-protein
fusion	I-protein
protein	I-protein
up-regulated	O
their	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
and	O
MHC	B-protein
class	I-protein
I	I-protein
and	I-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
their	O
secretion	O
of	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor-a	I-protein
,	O
and	O
granulocyte	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Furthermore	O
,	O
CD40	B-protein
ligation	O
of	O
a	O
HLA-A2+	B-cell_line
,	I-cell_line
MelanA/MART1+	I-cell_line
MM	I-cell_line
cell	I-cell_line
line	I-cell_line
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2-restricted	B-cell_line
,	I-cell_line
MelanA/MART-1-specific	I-cell_line
CTL	I-cell_line
clone	I-cell_line
.	O

Finally	O
,	O
CD40	B-protein
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40	B-protein
-CD40L	B-protein
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40	B-protein
-positive	O
immunogenic	O
human	O
MMs	O
.	O

[	NULL
CANCER	NULL
RESEARCH	NULL
59	NULL
,	NULL
1287-1294	NULL
,	NULL
March	NULL
15	NULL
,	NULL
1999	NULL
]	NULL
Stimulation	NULL
of	NULL
CD40	NULL
on	NULL
Immunogenic	NULL
Human	NULL
Malignant	NULL
Melanomas	NULL
Augments	NULL
Their	NULL
Cytotoxic	NULL
T	NULL
Lymphocyte-mediated	NULL
Lysis	NULL
and	NULL
Induces	NULL
Apoptosis	NULL
'	NULL
Achim	NULL
yon	NULL
Leoprechting	NULL
,	NULL
Pierre	NULL
van	NULL
der	NULL
Bruggen	NULL
,	NULL
Heike	NULL
L.	NULL
Pahl	NULL
,	NULL
Alejandro	NULL
Aruffo	NULL
,	NULL
and	NULL
Jan	NULL
C.	NULL
Simon	NULL
Institute	NULL
for	NULL
Biology	NULL
II	NULL
[	NULL
A.	NULL
v.	NULL
L.	NULL
]	NULL
and	NULL
Departments	NULL
of	NULL
Dermatology	NULL
[	NULL
A.	NULL
v.	NULL
L.	NULL
,	NULL
J.	NULL
C.	NULL
S.	NULL
]	NULL
and	NULL
Experimental	NULL
Anesthesiology	NULL
[	NULL
H.	NULL
L.P.	NULL
]	NULL
,	NULL
University	NULL
of	NULL
Freiburg	NULL
,	NULL
D-79104	NULL
Freiburg	NULL
,	NULL
Germany	NULL
;	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
,	NULL
Brussels	NULL
Branch	NULL
,	NULL
B-1200	NULL
Brussels	NULL
,	NULL
Belgium	NULL
[	NULL
P.	NULL
v.	NULL
d	NULL
.	NULL

B	NULL
.	NULL
]	NULL

;	NULL
and	NULL
Bristol-Myers	NULL
Squibb	NULL
Pharmaceutical	NULL
Research	NULL
Institute	NULL
,	NULL
Princeton	NULL
,	NULL
New	NULL
Jersey	NULL
08543	NULL
[	NULL
A	NULL
.	NULL

A	NULL
.	NULL
]	NULL

ABSTRACT	NULL
Here	NULL
,	NULL
we	NULL
report	NULL
the	NULL
functional	NULL
expression	NULL
of	NULL
CD40	NULL
on	NULL
human	NULL
malignant	NULL
melanomas	NULL
(	NULL
MMs	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
tumor	NULL
specimen	NULL
from	NULL
MM	NULL
precursor	NULL
lesions	NULL
,	NULL
primary	NULL
tumors	NULL
,	NULL
and	NULL
metastases	NULL
revealed	NULL
that	NULL
CD40	NULL
surface	NULL
expression	NULL
is	NULL
down-regulated	NULL
during	NULL
tumor	NULL
progression	NULL
.	NULL

CD40	NULL
expression	NULL
was	NULL
confirmed	NULL
in	NULL
7	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
established	NULL
from	NULL
immunogenic	NULL
primary	NULL
tumors	NULL
or	NULL
metastases	NULL
,	NULL
whereas	NULL
11	NULL
cell	NULL
lines	NULL
established	NULL
from	NULL
advanced	NULL
stages	NULL
were	NULL
CD40	NULL
negative	NULL
.	NULL

CD40	NULL
expression	NULL
could	NULL
be	NULL
enhanced	NULL
in	NULL
CD40-positive	NULL
MM	NULL
by	NULL
stimulation	NULL
with	NULL
IFN-y	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-	NULL
«	NULL
but	NULL
not	NULL
by	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-1B	NULL
or	NULL
CD40	NULL
triggering	NULL
.	NULL

CD40	NULL
ligation	NULL
on	NULL
MM	NULL
by	NULL
CD4O0L-transfected	NULL
murine	NULL
L-cells	NULL
or	NULL
by	NULL
a	NULL
soluble	NULL
CD4O0L	NULL
fusion	NULL
protein	NULL
up-regulated	NULL
their	NULL
expression	NULL
of	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
molecules	NULL
and	NULL
their	NULL
secretion	NULL
of	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
,	NULL
and	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
and	NULL
also	NULL
induced	NULL
a	NULL
rapid	NULL
activation	NULL
of	NULL
the	NULL
transcription	NULL
factor	NULL
nuclear	NULL
factor	NULL
xB	NULL
.	NULL

Furthermore	NULL
,	NULL
CD40	NULL
ligation	NULL
of	NULL
a	NULL
HLA-A2*	NULL
,	NULL
MelanA/MART1*	NULL
MM	NULL
cell	NULL
line	NULL
enhanced	NULL
its	NULL
susceptibility	NULL
to	NULL
specific	NULL
lysis	NULL
by	NULL
a	NULL
HLA-A2-restricted	NULL
,	NULL
MelanA/MART-1-specific	NULL
CTL	NULL
clone	NULL
.	NULL

Finally	NULL
,	NULL
CD40	NULL
ligation	NULL
induced	NULL
growth	NULL
inhibition	NULL
and	NULL
apoptosis	NULL
in	NULL
MM	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
CD40-CD40L	NULL
interactions	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
augmenting	NULL
antitumor	NULL
immunity	NULL
and	NULL
inducing	NULL
apoptosis	NULL
in	NULL
some	NULL
CD40-positive	NULL
immunogenic	NULL
human	NULL
MMs	NULL
.	NULL

INTRODUCTION	NULL
CD40	NULL
,	NULL
a	NULL
M	NULL
,	NULL
45,000-50,000	NULL
integral	NULL
membrane	NULL
protein	NULL
,	NULL
is	NULL
a	NULL
member	NULL
of	NULL
a	NULL
protein	NULL
family	NULL
that	NULL
includes	NULL
the	NULL
TNF-RI	NULL
,	NULL
*	NULL
TNF-RIL	NULL
,	NULL
p75	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
,	NULL
CD30	NULL
,	NULL
CD27	NULL
,	NULL
Fas	NULL
,	NULL
and	NULL
others	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Expression	NULL
and	NULL
function	NULL
of	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
have	NULL
been	NULL
studied	NULL
intensively	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Several	NULL
reports	NULL
show	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
CD40	NULL
is	NULL
not	NULL
restricted	NULL
to	NULL
cells	NULL
of	NULL
the	NULL
B	NULL
lineage	NULL
because	NULL
CD40	NULL
is	NULL
functionally	NULL
expressed	NULL
on	NULL
dendritic	NULL
cells	NULL
,	NULL
monocytes	NULL
,	NULL
vascular	NULL
endothelial	NULL
cells	NULL
,	NULL
keratinocytes	NULL
,	NULL
and	NULL
fibroblasts	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

The	NULL
ligand	NULL
for	NULL
CD40	NULL
(	NULL
CD4O0L	NULL
,	NULL
CD154	NULL
,	NULL
TRAP	NULL
,	NULL
or	NULL
gp39	NULL
)	NULL
,	NULL
a	NULL
type	NULL
II	NULL
membrane	NULL
protein	NULL
with	NULL
significant	NULL
sequence	NULL
homology	NULL
to	NULL
TNF	NULL
,	NULL
is	NULL
primarily	NULL
expressed	NULL
on	NULL
activated	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
but	NULL
is	NULL
also	NULL
found	NULL
on	NULL
stimulated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
mast	NULL
cells	NULL
,	NULL
eosinophils	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
dendritic	NULL
cells	NULL
(	NULL
2	NULL
,	NULL
4	NULL
)	NULL
.	NULL

CD40	NULL
ligation	NULL
induces	NULL
functional	NULL
changes	NULL
in	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
,	NULL
including	NULL
the	NULL
up-regulation	NULL
of	NULL
MHC	NULL
,	NULL
costimulatory	NULL
,	NULL
and	NULL
adhesion	NULL
molecules	NULL
and	NULL
the	NULL
secretion	NULL
of	NULL
cytokines	NULL
,	NULL
which	NULL
all	NULL
participate	NULL
in	NULL
T	NULL
cell-mediated	NULL
immune	NULL
re	NULL
Received	NULL
10/27/98	NULL
;	NULL
accepted	NULL
1/21/99	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

Supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Deutsche	NULL
Forschungsgemeinschaft	NULL
(	NULL
Si-397/7-1	NULL
)	NULL
and	NULL
the	NULL
Zentrum	NULL
fiir	NULL
klinische	NULL
Forschung	NULL
I	NULL
,	NULL
Freiburg	NULL
University	NULL
Medical	NULL
Center	NULL
.	NULL

?	NULL

To	NULL
whom	NULL
requests	NULL
for	NULL
reprints	NULL
should	NULL
be	NULL
addressed	NULL
,	NULL
at	NULL
Department	NULL
of	NULL
Dermatology	NULL
,	NULL
University	NULL
of	NULL
Freiburg	NULL
,	NULL
Hauptstrasse	NULL
7	NULL
,	NULL
D-79104	NULL
Freiburg	NULL
,	NULL
Germany	NULL
.	NULL

Phone	NULL
:	NULL
49-761-270-6740	NULL
;	NULL
Fax	NULL
:	NULL
49-761-270-6745	NULL
;	NULL
E-mail	NULL
:	NULL
simonj	NULL
@	NULL
haut.ukl.uni-freiburg.de	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TNF	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
;	NULL
TNF-R	NULL
,	NULL
TNF	NULL
receptor	NULL
;	NULL
MM	NULL
,	NULL
malignant	NULL
melanoma	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
NF-KB	NULL
,	NULL
nuclear	NULL
factor	NULL
B	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
sTNF-RI	NULL
,	NULL
soluble	NULL
TNF-RI	NULL
;	NULL
FACS	NULL
,	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
;	NULL
MFI	NULL
,	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
;	NULL
cMFI	NULL
,	NULL
corrected	NULL
MFI	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
PMSF	NULL
,	NULL
phenyl-methylsulfony	NULL
]	NULL
fluoride	NULL
;	NULL
APC	NULL
,	NULL
antigen-presenting	NULL
cell	NULL
;	NULL
ICAM-1	NULL
,	NULL
intercellular	NULL
adhesion	NULL
molecule-1	NULL
.	NULL

sponses	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
CD40	NULL
stimulus	NULL
is	NULL
an	NULL
important	NULL
factor	NULL
for	NULL
the	NULL
induction	NULL
of	NULL
CTLs	NULL
(	NULL
4-9	NULL
)	NULL
.	NULL

However	NULL
,	NULL
consequences	NULL
of	NULL
CD40	NULL
stimulation	NULL
are	NULL
not	NULL
limited	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
T	NULL
cell-	NULL
or	NULL
B	NULL
cell-mediated	NULL
immune	NULL
responses	NULL
because	NULL
cross-linking	NULL
of	NULL
CD40	NULL
has	NULL
also	NULL
profound	NULL
effects	NULL
on	NULL
cell	NULL
proliferation	NULL
and	NULL
viability	NULL
.	NULL

Ligation	NULL
of	NULL
CD40	NULL
results	NULL
in	NULL
enhanced	NULL
proliferation	NULL
of	NULL
fibroblasts	NULL
and	NULL
B	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
but	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
is	NULL
described	NULL
for	NULL
keratinocytes	NULL
and	NULL
neoplastic	NULL
cells	NULL
such	NULL
as	NULL
B	NULL
lymphomas	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
following	NULL
CD40	NULL
signaling	NULL
apoptosis	NULL
is	NULL
induced	NULL
in	NULL
the	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
XG2	NULL
(	NULL
10	NULL
)	NULL
and	NULL
in	NULL
transformed	NULL
cells	NULL
of	NULL
mesenchymal	NULL
and	NULL
epithelial	NULL
origin	NULL
(	NULL
11	NULL
)	NULL
.	NULL

MM	NULL
has	NULL
been	NULL
described	NULL
as	NULL
an	NULL
immunogenic	NULL
tumor	NULL
,	NULL
which	NULL
is	NULL
infiltrated	NULL
by	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
12	NULL
)	NULL
.	NULL

MMs	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
express	NULL
both	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
molecules	NULL
and	NULL
to	NULL
stimulate	NULL
the	NULL
proliferation	NULL
of	NULL
autologous	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
lymphocytes	NULL
in	NULL
vitro	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
human	NULL
MMs	NULL
are	NULL
susceptible	NULL
to	NULL
specific	NULL
lysis	NULL
by	NULL
CD8	NULL
*	NULL
CTLs	NULL
that	NULL
recognize	NULL
MHC	NULL
class	NULL
I-associated	NULL
peptides	NULL
derived	NULL
from	NULL
different	NULL
melanoma-specific	NULL
antigens	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
human	NULL
MM	NULL
can	NULL
produce	NULL
a	NULL
range	NULL
of	NULL
cytokines	NULL
capable	NULL
of	NULL
enhancing	NULL
T	NULL
cell-mediated	NULL
immunity	NULL
,	NULL
including	NULL
IL-1	NULL
,	NULL
TNF-a	NULL
,	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
15	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
cytokine	NULL
expression	NULL
of	NULL
MM	NULL
is	NULL
regulated	NULL
are	NULL
largely	NULL
unknown	NULL
.	NULL

A	NULL
potent	NULL
transcription	NULL
factor	NULL
of	NULL
these	NULL
cytokines	NULL
is	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
activated	NULL
,	NULL
among	NULL
other	NULL
stimuli	NULL
,	NULL
by	NULL
CD40	NULL
triggering	NULL
on	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

16	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
has	NULL
been	NULL
described	NULL
that	NULL
MM	NULL
cells	NULL
express	NULL
CD40	NULL
both	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
but	NULL
little	NULL
is	NULL
known	NULL
about	NULL
its	NULL
function	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrate	NULL
in	NULL
some	NULL
CD4O0-positive	NULL
immunogenic	NULL
human	NULL
MM	NULL
that	NULL
CD40/CD40L-mediated	NULL
signals	NULL
activate	NULL
transcription	NULL
factor	NULL
NF-B	NULL
,	NULL
enhance	NULL
the	NULL
production	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
as	NULL
well	NULL
as	NULL
of	NULL
immunorelevant	NULL
surface	NULL
molecules	NULL
,	NULL
and	NULL
augment	NULL
their	NULL
specific	NULL
CTL-mediated	NULL
lysis	NULL
.	NULL

Moreover	NULL
,	NULL
CD40	NULL
triggering	NULL
markedly	NULL
inhibits	NULL
the	NULL
growth	NULL
of	NULL
these	NULL
MM	NULL
cell	NULL
lines	NULL
via	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
mAbs	NULL
and	NULL
Reagents	NULL
.	NULL

mAb	NULL
with	NULL
specificity	NULL
for	NULL
the	NULL
following	NULL
human	NULL
antigens	NULL
were	NULL
used	NULL
:	NULL
CD40	NULL
(	NULL
EA-5	NULL
;	NULL
Calbiochem	NULL
,	NULL
Bad	NULL
Soden	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
CD44	NULL
(	NULL
MEM-85	NULL
;	NULL
Monosan	NULL
,	NULL
Uden	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
;	NULL
CD54	NULL
(	NULL
84H10	NULL
;	NULL
Immunotech	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
CD4O0L	NULL
(	NULL
TRAP	NULL
)	NULL
;	NULL
anti-HLA-ABC	NULL
(	NULL
W6/32	NULL
;	NULL
Sigma	NULL
,	NULL
Deisenhofen	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
and	NULL
anti-HLA-DR	NULL
(	NULL
Ti36	NULL
)	NULL
,	NULL
B7.1	NULL
(	NULL
BB1	NULL
)	NULL
,	NULL
B7.2	NULL
(	NULL
IT2.2	NULL
)	NULL
,	NULL
CD95	NULL
(	NULL
DX2	NULL
)	NULL
,	NULL
CD95L	NULL
(	NULL
NOK-1	NULL
)	NULL
,	NULL
and	NULL
antimouse	NULL
H2-K	NULL
``	NULL
mAb	NULL
(	NULL
36-7-5	NULL
)	NULL
,	NULL
all	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
anti-CD40	NULL
mAb	NULL
(	NULL
G28-5	NULL
)	NULL
,	NULL
anti-CD40L	NULL
mAb	NULL
(	NULL
39-1.106	NULL
)	NULL
,	NULL
and	NULL
soluble	NULL
CD4O0L	NULL
fusion	NULL
protein	NULL
(	NULL
sCD40L	NULL
)	NULL
,	NULL
consisting	NULL
of	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
mouse	NULL
CD8	NULL
and	NULL
the	NULL
extracellular	NULL
domain	NULL
of	NULL
human	NULL
CD4O0L	NULL
,	NULL
were	NULL
described	NULL
previously	NULL
(	NULL
19	NULL
)	NULL
.	NULL

The	NULL
fusion	NULL
protein	NULL
was	NULL
used	NULL
in	NULL
a	NULL
1:3	NULL
dilution	NULL
of	NULL
supernatants	NULL
collected	NULL
from	NULL
transfected	NULL
COS	NULL
cells	NULL
unless	NULL
stated	NULL
otherwise	NULL
.	NULL

Isotype-matched	NULL
control	NULL
mAbs	NULL
were	NULL
purchased	NULL
from	NULL
Immunotech	NULL
.	NULL

The	NULL
following	NULL
recombinant	NULL
human	NULL
cytokines	NULL
,	NULL
receptors	NULL
,	NULL
and	NULL
fusion	NULL
proteins	NULL
were	NULL
used	NULL
:	NULL
IL-2	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
IL-1B	NULL
(	NULL
PromoCell	NULL
,	NULL
Heidelberg	NULL
,	NULL
and	NULL
Genzyme	NULL
,	NULL
Riisselsheim	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
TNF-	NULL
«	NULL
and	NULL
sTNF-RI	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
Wiesbaden	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
APO1/Fas-immunoglobulin	NULL
(	NULL
Alexis	NULL
,	NULL
Griinberg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Cell	NULL
Lines	NULL
,	NULL
Media	NULL
,	NULL
and	NULL
Cell	NULL
Culture	NULL
.	NULL

The	NULL
human	NULL
melanoma	NULL
cell	NULL
lines	NULL
MIRW	NULL
,	NULL
MM1	NULL
,	NULL
HT144	NULL
,	NULL
and	NULL
SK-Me128	NULL
were	NULL
purchased	NULL
from	NULL
American	NULL
Type	NULL
1287	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
Culture	NULL
Collection	NULL
(	NULL
Manassas	NULL
,	NULL
VA	NULL
)	NULL
;	NULL
MV3	NULL
and	NULL
1F6	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
P.	NULL
van	NULL
Muijen	NULL
(	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Nijmegen	NULL
,	NULL
Nijmegen	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
;	NULL
Termel	NULL
1-3	NULL
were	NULL
generated	NULL
in	NULL
our	NULL
laboratory	NULL
from	NULL
lymph	NULL
node	NULL
melanoma	NULL
metastases	NULL
,	NULL
384/33	NULL
and	NULL
397/22	NULL
,	NULL
which	NULL
were	NULL
generated	NULL
from	NULL
spontaneously	NULL
regressing	NULL
MM	NULL
and	NULL
were	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
A.	NULL
Mackensen	NULL
(	NULL
Department	NULL
of	NULL
Medicine	NULL
I	NULL
,	NULL
University	NULL
of	NULL
Freiburg	NULL
,	NULL
Freiburg	NULL
,	NULL
Germany	NULL
)	NULL
;	NULL
and	NULL
LB39-Mel	NULL
,	NULL
LB373	NULL
,	NULL
LB265	NULL
,	NULL
LB33-Mel	NULL
,	NULL
LB24	NULL
,	NULL
LG2-Mel	NULL
,	NULL
and	NULL
MZ2-Mel.43	NULL
and	NULL
the	NULL
MelanA/MART-1-specific	NULL
CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
were	NULL
established	NULL
at	NULL
the	NULL
Ludwig	NULL
Institute	NULL
for	NULL
Cancer	NULL
Research	NULL
(	NULL
Brussels	NULL
,	NULL
Belgium	NULL
)	NULL
.	NULL

The	NULL
Daudi	NULL
cell	NULL
line	NULL
and	NULL
the	NULL
fibroblast	NULL
cell	NULL
line	NULL
L-M	NULL
from	NULL
C3H	NULL
mice	NULL
(	NULL
the	NULL
CD4O0L-transfected	NULL
and	NULL
the	NULL
untransfected	NULL
control	NULL
cell	NULL
line	NULL
)	NULL
were	NULL
obtained	NULL
from	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

The	NULL
HLA-A2-positive	NULL
transporters	NULL
associated	NULL
with	NULL
antigen	NULL
processing-deficient	NULL
T-B-lymphoblast	NULL
hybridoma	NULL
T2	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
20	NULL
)	NULL
.	NULL

RPMI	NULL
1640	NULL
(	NULL
Biochrom	NULL
,	NULL
Berlin	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
Iscove	NULL
's	NULL
modified	NULL
DMEM	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
,	NULL
Eggenstein	NULL
,	NULL
Germany	NULL
)	NULL
were	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
(	NULL
PAA	NULL
,	NULL
Coelbe	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
nonessential	NULL
amino	NULL
acids	NULL
,	NULL
50	NULL
pg/ml	NULL
penicillin-streptomycin	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
all	NULL
from	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Cultures	NULL
of	NULL
nontransformed	NULL
melanocytes	NULL
were	NULL
established	NULL
from	NULL
human	NULL
neonatal	NULL
foreskin	NULL
by	NULL
digestion	NULL
with	NULL
dispase	NULL
(	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
)	NULL
and	NULL
trypsin	NULL
(	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
)	NULL
and	NULL
maintained	NULL
in	NULL
selective	NULL
melanocyte	NULL
growth	NULL
medium	NULL
(	NULL
PromoCell	NULL
)	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
at	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

Second-to	NULL
fifth-passage	NULL
melanocyte	NULL
cultures	NULL
were	NULL
used	NULL
for	NULL
all	NULL
experiments	NULL
.	NULL

MM	NULL
cells	NULL
and	NULL
murine	NULL
L	NULL
cells	NULL
were	NULL
cultivated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
at	NULL
5	NULL
and	NULL
8	NULL
%	NULL
CO	NULL
,	NULL
,	NULL
respectively	NULL
.	NULL

CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
,	NULL
recognizing	NULL
the	NULL
MelanA/MART-1	NULL
peptide	NULL
27-35	NULL
(	NULL
EAAGIGILTV	NULL
)	NULL
,	NULL
was	NULL
maintained	NULL
in	NULL
culture	NULL
as	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
CTLs	NULL
were	NULL
transferred	NULL
every	NULL
7	NULL
days	NULL
to	NULL
2	NULL
ml	NULL
of	NULL
Iscove	NULL
's	NULL
modified	NULL
DMEM	NULL
containing	NULL
10	NULL
%	NULL
human	NULL
serum	NULL
and	NULL
50	NULL
units/ml	NULL
IL-2	NULL
,	NULL
1	NULL
X	NULL
10°	NULL
T2	NULL
cells	NULL
(	NULL
y-irradiated	NULL
,	NULL
100	NULL
Gy	NULL
)	NULL
pulsed	NULL
with	NULL
1	NULL
um	NULL
peptide	NULL
,	NULL
and	NULL
1.5	NULL
X	NULL
10°	NULL
EBV-transformed	NULL
feeder	NULL
B	NULL
cells	NULL
(	NULL
y-irradiated	NULL
,	NULL
100	NULL
Gy	NULL
)	NULL
.	NULL

Immunohistochemistry	NULL
.	NULL

After	NULL
the	NULL
patients	NULL
gave	NULL
their	NULL
informed	NULL
consent	NULL
,	NULL
we	NULL
obtained	NULL
punch	NULL
biopsies	NULL
at	NULL
the	NULL
time	NULL
of	NULL
surgery	NULL
from	NULL
tumors	NULL
of	NULL
patients	NULL
with	NULL
primary	NULL
melanoma	NULL
(	NULL
#	NULL
=	NULL
13	NULL
)	NULL
,	NULL
cutaneous	NULL
metastases	NULL
of	NULL
MM	NULL
(	NULL
n	NULL
=	NULL
10	NULL
)	NULL
,	NULL
or	NULL
benign	NULL
melanocytic	NULL
nevi	NULL
(	NULL
n	NULL
=	NULL
9	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
snap-frozen	NULL
immediately	NULL
and	NULL
stored	NULL
in	NULL
liquid	NULL
nitrogen	NULL
until	NULL
use	NULL
.	NULL

Five-wm	NULL
cryosections	NULL
of	NULL
tissue	NULL
samples	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
CD4O-specific	NULL
mAb	NULL
EA-5	NULL
(	NULL
Calbiochem	NULL
)	NULL
or	NULL
an	NULL
appropriate	NULL
control	NULL
mAb	NULL
,	NULL
using	NULL
a	NULL
four-step	NULL
immunohistochemical	NULL
staining	NULL
protocol	NULL
involving	NULL
the	NULL
avidin-biotin	NULL
complex	NULL
.	NULL

Staining	NULL
was	NULL
evaluated	NULL
using	NULL
a	NULL
Zeiss	NULL
Axioscope	NULL
equipped	NULL
with	NULL
a	NULL
MC100	NULL
camera	NULL
system	NULL
(	NULL
Gottingen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Immunostaining	NULL
and	NULL
Flow	NULL
Cytometry	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
in	NULL
PBS	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
unconjugated	NULL
primary	NULL
mAb	NULL
(	NULL
antigen-specific	NULL
or	NULL
control	NULL
IgG	NULL
)	NULL
followed	NULL
by	NULL
FITC-labeled	NULL
F	NULL
(	NULL
ab	NULL
)	NULL
,	NULL
fragments	NULL
of	NULL
goat	NULL
antimouse	NULL
IgG	NULL
(	NULL
Dianova	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
analyzed	NULL
with	NULL
a	NULL
FACScan	NULL
using	NULL
the	NULL
CellQuest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Propidium	NULL
iodide	NULL
(	NULL
5	NULL
ug/ml	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
added	NULL
to	NULL
exclude	NULL
dead	NULL
cells	NULL
by	NULL
appropriate	NULL
gating	NULL
.	NULL

A	NULL
total	NULL
of	NULL
10°	NULL
viable	NULL
cells	NULL
per	NULL
sample	NULL
were	NULL
analyzed	NULL
and	NULL
MFIs	NULL
determined	NULL
using	NULL
CellQuest	NULL
software	NULL
.	NULL

cMFIs	NULL
were	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
following	NULL
formula	NULL
:	NULL
(	NULL
antigen-specific	NULL
mAb	NULL
)	NULL
__	NULL
(	NULL
control	NULL
mAb	NULL
)	NULL
..	NULL
(	NULL
antigen-specific	NULL
mAb	NULL
)	NULL
MFT	NULL
=	NULL
Northern	NULL
Blot	NULL
Analysis	NULL
of	NULL
CD40	NULL
RNA	NULL
.	NULL

MM	NULL
cells	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
shock-frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
after	NULL
detachment	NULL
from	NULL
culture	NULL
flasks	NULL
with	NULL
EDTA	NULL
(	NULL
5	NULL
mM	NULL
in	NULL
PBS	NULL
;	NULL
Sigma	NULL
)	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
.	NULL

Total	NULL
cellular	NULL
RNA	NULL
was	NULL
extracted	NULL
using	NULL
a	NULL
guanidinium-isothiocyanate	NULL
containing	NULL
lysis	NULL
buffer	NULL
with	NULL
subsequent	NULL
purification	NULL
on	NULL
a	NULL
CsCl	NULL
gradient	NULL
.	NULL

Fifteen	NULL
ug	NULL
of	NULL
the	NULL
RNA	NULL
were	NULL
subjected	NULL
to	NULL
electrophoresis	NULL
on	NULL
1	NULL
%	NULL
agarose	NULL
gels	NULL
and	NULL
transferred	NULL
onto	NULL
Hy-bond-N+	NULL
nylon	NULL
membranes	NULL
(	NULL
Amersham	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
by	NULL
Northern	NULL
blotting	NULL
.	NULL

For	NULL
blot	NULL
hybridization	NULL
,	NULL
a	NULL
full-length	NULL
CD40	NULL
probe	NULL
was	NULL
labeled	NULL
with	NULL
[	NULL
°°P	NULL
]	NULL
dCTP	NULL
(	NULL
Amersham	NULL
)	NULL
by	NULL
the	NULL
random	NULL
primer	NULL
method	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
blots	NULL
were	NULL
exposed	NULL
for	NULL
autoradiography	NULL
and	NULL
films	NULL
were	NULL
scanned	NULL
on	NULL
a	NULL
Herolab	NULL
EA.S.Y	NULL
RH3	NULL
(	NULL
Herolab	NULL
,	NULL
Wiesloch	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
densitometry	NULL
and	NULL
digital	NULL
processing	NULL
of	NULL
picture	NULL
positives	NULL
.	NULL

MM	NULL
Stimulation	NULL
via	NULL
CD40	NULL
.	NULL

Human	NULL
melanoma	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
h	NULL
at	NULL
37°C/5	NULL
%	NULL
CO	NULL
,	NULL
in	NULL
medium	NULL
with	NULL
or	NULL
without	NULL
200	NULL
units/ml	NULL
IFN-y	NULL
unless	NULL
stated	NULL
otherwise	NULL
and	NULL
then	NULL
washed	NULL
twice	NULL
with	NULL
PBS	NULL
.	NULL

They	NULL
were	NULL
then	NULL
stimulated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
sCD4O0L	NULL
or	NULL
with	NULL
sCD4O0L	NULL
preincubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
the	NULL
neutralizing	NULL
anti-CD40L	NULL
mAb	NULL
39-1.106	NULL
(	NULL
10	NULL
pg/m	NULL
!	NULL
)	NULL

.	NULL

Alternatively	NULL
,	NULL
equal	NULL
numbers	NULL
of	NULL
melanoma	NULL
cells	NULL
,	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
pretreatment	NULL
,	NULL
were	NULL
cultured	NULL
on	NULL
a	NULL
monolayer	NULL
of	NULL
mitomycin	NULL
C-treated	NULL
(	NULL
50	NULL
ug/ml	NULL
,	NULL
30	NULL
min	NULL
at	NULL
25°C	NULL
)	NULL
CD4O0L*	NULL
L-cells	NULL
or	NULL
control	NULL
L-cells	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C/5	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
detached	NULL
with	NULL
2	NULL
mM	NULL
EDTA/PBS	NULL
,	NULL
and	NULL
L	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
immunomagnetic	NULL
separation	NULL
after	NULL
incubation	NULL
with	NULL
a	NULL
H2-K	NULL
``	NULL
*-specific	NULL
mAb	NULL
using	NULL
the	NULL
Dynabeads	NULL
system	NULL
(	NULL
Dynal	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Cytokine	NULL
ELISA	NULL
.	NULL

Cell	NULL
culture	NULL
supernatants	NULL
were	NULL
assayed	NULL
for	NULL
the	NULL
following	NULL
human	NULL
cytokines	NULL
by	NULL
specific	NULL
ELISA	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instruc-tions	NULL
:	NULL
IL-1	NULL
B	NULL
,	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
IL-10	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
,	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
and	NULL
GM-CSF	NULL
(	NULL
all	NULL
from	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
values	NULL
of	NULL
triplicate	NULL
measurements	NULL
*	NULL
SD	NULL
.	NULL

EMSA	NULL
.	NULL

EMSA	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
total	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
using	NULL
a	NULL
high-salt	NULL
detergent	NULL
buffer	NULL
[	NULL
Totex	NULL
;	NULL
20	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
350	NULL
mm	NULL
NaCl	NULL
,	NULL
20	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
(	NULL
w/v	NULL
)	NULL
NP40	NULL
,	NULL
1	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mm	NULL
EGTA	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.1	NULL
%	NULL
PMSF	NULL
,	NULL
and	NULL
1	NULL
%	NULL
aprotinin	NULL
]	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
by	NULL
centrifugation	NULL
,	NULL
washed	NULL
once	NULL
in	NULL
ice-cold	NULL
PBS	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
resuspended	NULL
in	NULL
four	NULL
cell	NULL
volumes	NULL
of	NULL
Totex	NULL
buffer	NULL
.	NULL

After	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
the	NULL
lysates	NULL
were	NULL
centrifuged	NULL
for	NULL
5	NULL
min	NULL
at	NULL
13,000	NULL
X	NULL
g	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
protein	NULL
content	NULL
of	NULL
the	NULL
supernatant	NULL
was	NULL
determined	NULL
and	NULL
equal	NULL
amounts	NULL
of	NULL
protein	NULL
(	NULL
10-20	NULL
ug	NULL
)	NULL
added	NULL
to	NULL
a	NULL
reaction	NULL
mixture	NULL
containing	NULL
20	NULL
ug	NULL
of	NULL
BSA	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Boehringer-Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
2	NULL
pl	NULL
of	NULL
buffer	NULL
D+	NULL
[	NULL
20	NULL
mM	NULL
Hepes	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
20	NULL
%	NULL
glycerin	NULL
,	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
0.5	NULL
mm	NULL
EDTA	NULL
,	NULL
0.25	NULL
%	NULL
NP4O0	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
PMSF	NULL
]	NULL
,	NULL
4	NULL
l	NULL
of	NULL
buffer	NULL
F	NULL
(	NULL
20	NULL
%	NULL
Ficoll	NULL
400	NULL
,	NULL
100	NULL
mm	NULL
Hepes	NULL
,	NULL
300	NULL
mM	NULL
KCI	NULL
,	NULL
10	NULL
mm	NULL
DTT	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
PMSF	NULL
)	NULL
,	NULL
and	NULL
100,000	NULL
epm	NULL
(	NULL
Cerenkov	NULL
)	NULL
of	NULL
a	NULL
P-labeled	NULL
oligonucleotide	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
.	NULL

Samples	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
25	NULL
min	NULL
.	NULL

NF-KB	NULL
oligonucleotide	NULL
(	NULL
Promega	NULL
,	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
was	NULL
labeled	NULL
using	NULL
[	NULL
y-*°P	NULL
]	NULL
ATP	NULL
(	NULL
3000	NULL
Ci/mmol	NULL
;	NULL
Amer-sham	NULL
)	NULL
and	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

Proliferation	NULL
Assay	NULL
.	NULL

MM	NULL
cells	NULL
at	NULL
10	NULL
X	NULL
10°	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
,	NULL
and	NULL
2	NULL
X	NULL
10°	NULL
were	NULL
cultured	NULL
on	NULL
monolayers	NULL
of	NULL
2	NULL
X	NULL
10°	NULL
CD4O0L-transfected	NULL
or	NULL
untransfected	NULL
mitomycin	NULL
C-treated	NULL
L-cells	NULL
in	NULL
96-well	NULL
flat-bottomed	NULL
plates	NULL
(	NULL
Becton	NULL
Dickin-son	NULL
)	NULL
for	NULL
36	NULL
h.	NULL
In	NULL
some	NULL
experiments	NULL
,	NULL
either	NULL
biologically	NULL
active	NULL
sTNF-RI	NULL
(	NULL
0.5	NULL
pg/ml	NULL
)	NULL
or	NULL
APO1/Fas-immunoglobulin	NULL
(	NULL
20	NULL
ug/ml	NULL
)	NULL
to	NULL
neutralize	NULL
MM	NULL
derived	NULL
TNF-a	NULL
or	NULL
APO1/FasL	NULL
was	NULL
added	NULL
to	NULL
the	NULL
coculture	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
JThymidine	NULL
(	NULL
Amersham	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
was	NULL
added	NULL
at	NULL
1	NULL
wCi/well	NULL
for	NULL
the	NULL
last	NULL
18	NULL
h	NULL
of	NULL
culture	NULL
.	NULL

Plates	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
Canberra	NULL
Packard	NULL
Filter-Mate	NULL
(	NULL
Canberra	NULL
Packard	NULL
,	NULL
Dreieich	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
incorporation	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
was	NULL
determined	NULL
by	NULL
liquid	NULL
scintillation	NULL
spectroscopy	NULL
using	NULL
a	NULL
TopCount	NULL
device	NULL
(	NULL
Canberra	NULL
Packard	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
cpm	NULL
+	NULL
SD	NULL
of	NULL
quadruple	NULL
cultures	NULL
.	NULL

Cytotoxicity	NULL
Assay	NULL
.	NULL

*'Cr-release	NULL
assays	NULL
,	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
13	NULL
)	NULL
,	NULL
were	NULL
used	NULL
to	NULL
assess	NULL
cytotoxicity	NULL
rates	NULL
of	NULL
the	NULL
CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
(	NULL
spe-cific	NULL
for	NULL
MelanA/MART1	NULL
peptide	NULL
27-35	NULL
)	NULL
against	NULL
the	NULL
MM	NULL
cell	NULL
line	NULL
LB39-Mel	NULL
(	NULL
HLA-A2*	NULL
,	NULL
MelanA/MART1*	NULL
)	NULL
or	NULL
against	NULL
the	NULL
HLA-A2*	NULL
TAP-deficient	NULL
T-B	NULL
lymphoblast	NULL
line	NULL
T2	NULL
.	NULL

LB39-Mel	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
priming	NULL
(	NULL
200	NULL
units/ml	NULL
,	NULL
24	NULL
h	NULL
)	NULL
were	NULL
cocultured	NULL
with	NULL
mitomycin	NULL
C-treated	NULL
L-cells	NULL
(	NULL
CD4O0L-transfected	NULL
or	NULL
control	NULL
)	NULL
and	NULL
then	NULL
purified	NULL
by	NULL
immunomagnetic	NULL
separation	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Thereafter	NULL
,	NULL
target	NULL
cells	NULL
(	NULL
either	NULL
LB39-Mel	NULL
or	NULL
T2	NULL
)	NULL
were	NULL
labeled	NULL
with	NULL
1	NULL
mCi/ml	NULL
Na	NULL
;	NULL
,	NULL
°'CrO	NULL
,	NULL
(	NULL
Amersham	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C/8	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
and	NULL
then	NULL
washed	NULL
with	NULL
medium	NULL
.	NULL

T2	NULL
cells	NULL
were	NULL
either	NULL
pulsed	NULL
with	NULL
MelanA/MARTI1	NULL
peptide	NULL
EAAGIGILTV	NULL
at	NULL
1	NULL
uM	NULL
immediately	NULL
prior	NULL
to	NULL
use	NULL
(	NULL
positive	NULL
control	NULL
)	NULL
or	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
.	NULL

°'Cr-labeled	NULL
target	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
LB373-CTL-246/15	NULL
at	NULL
the	NULL
indicated	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
pl	NULL
in	NULL
V-bottomed	NULL
96-well	NULL
plates	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Spontaneous	NULL
°'Cr-release	NULL
was	NULL
determined	NULL
by	NULL
culture	NULL
of	NULL
identical	NULL
numbers	NULL
of	NULL
labeled	NULL
target	NULL
cells	NULL
without	NULL
CTLs	NULL
;	NULL
maximum	NULL
°'Cr-release	NULL
by	NULL
addition	NULL
of	NULL
1	NULL
%	NULL
Triton	NULL
X-100-PBS	NULL
to	NULL
target	NULL
cells	NULL
.	NULL

Fifty	NULL
wl	NULL
per	NULL
well	NULL
were	NULL
then	NULL
transferred	NULL
onto	NULL
Luma	NULL
plates	NULL
(	NULL
Canberra	NULL
Packard	NULL
)	NULL
dried	NULL
and	NULL
analyzed	NULL
using	NULL
a	NULL
TopCount	NULL
device	NULL
.	NULL

Percentage	NULL
of	NULL
specific	NULL
lysis	NULL
was	NULL
calculated	NULL
according	NULL
to	NULL
the	NULL
formula	NULL
:	NULL
%	NULL
specific	NULL
lysis	NULL
=	NULL
[	NULL
(	NULL
test	NULL
*'Cr	NULL
release	NULL
-	NULL
spontaneous	NULL
*'Cr	NULL
release	NULL
)	NULL
/	NULL
(	NULL
maximum	NULL
°'Cr	NULL
release	NULL
-	NULL
spontaneous	NULL
*'Cr	NULL
release	NULL
]	NULL
X	NULL
100	NULL
Detection	NULL
of	NULL
Apoptosis	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
viable	NULL
melanoma	NULL
cells	NULL
after	NULL
CD40	NULL
stimulation	NULL
or	NULL
no	NULL
treatment	NULL
was	NULL
compared	NULL
by	NULL
FACS	NULL
analysis	NULL
after	NULL
staining	NULL
with	NULL
propidium	NULL
iodide	NULL
(	NULL
5	NULL
ug/ml	NULL
)	NULL
in	NULL
PBS	NULL
.	NULL

For	NULL
detection	NULL
of	NULL
DNA	NULL
laddering	NULL
,	NULL
MIRW	NULL
or	NULL
LB39-Mel	NULL
,	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
priming	NULL
,	NULL
were	NULL
stimulated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
L-cells	NULL
(	NULL
CD4O0L*	NULL
or	NULL
untransfected	NULL
controls	NULL
)	NULL
or	NULL
with	NULL
sCD40L	NULL
as	NULL
described	NULL
above	NULL
.	NULL

For	NULL
analysis	NULL
of	NULL
total	NULL
cellular	NULL
DNA	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
,	NULL
10°	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
TE	NULL
buffer	NULL
[	NULL
10	NULL
mm	NULL
Tris	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
-1	NULL
mM	NULL
EDTA	NULL
]	NULL
followed	NULL
by	NULL
cell	NULL
lysis	NULL
with	NULL
TTE	NULL
buffer	NULL
(	NULL
TE	NULL
buffer	NULL
+	NULL
0.2	NULL
%	NULL
1288	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
Triton	NULL
X-100	NULL
)	NULL
.	NULL

DNA	NULL
was	NULL
extracted	NULL
by	NULL
incubation	NULL
of	NULL
cell	NULL
lysates	NULL
with	NULL
ice-cold	NULL
TTE	NULL
buffer	NULL
,	NULL
2-propanol	NULL
,	NULL
and	NULL
5	NULL
M	NULL
NaCl	NULL
(	NULL
5:7:1	NULL
)	NULL
at	NULL
4°C	NULL
overnight	NULL
.	NULL

Lysates	NULL
were	NULL
then	NULL
centrifuged	NULL
at	NULL
14,000	NULL
rpm	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
DNA-containing	NULL
pellet	NULL
was	NULL
air-dried	NULL
for	NULL
3	NULL
h	NULL
at	NULL
RT	NULL
.	NULL

After	NULL
solubilization	NULL
of	NULL
the	NULL
pellet	NULL
with	NULL
TE	NULL
buffer	NULL
,	NULL
DNA	NULL
samples	NULL
were	NULL
separated	NULL
in	NULL
2	NULL
%	NULL
agarose/Tris-borate-EDTA	NULL
gels	NULL
.	NULL

Afterward	NULL
,	NULL
DNA	NULL
was	NULL
stained	NULL
with	NULL
ethidium	NULL
bromide	NULL
,	NULL
and	NULL
gels	NULL
were	NULL
photographed	NULL
using	NULL
a	NULL
Herolab	NULL
E.A.S.Y	NULL
RH3	NULL
device	NULL
.	NULL

Alternatively	NULL
,	NULL
detection	NULL
of	NULL
DNA	NULL
fragmentation	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
terminal	NULL
deoxynucleotidyltransferase-mediated	NULL
dUTP-X	NULL
nick	NULL
end	NULL
labeling	NULL
assay	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
10°	NULL
MM	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
the	NULL
in	NULL
situ	NULL
cell	NULL
death	NULL
detection	NULL
kit	NULL
from	NULL
Boehringer	NULL
(	NULL
Mannheim	NULL
,	NULL
Germany	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
and	NULL
subsequently	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
using	NULL
CellQuest	NULL
software	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

1	NULL
.	NULL

CD40	NULL
expression	NULL
in	NULL
human	NULL
melanoma	NULL
.	NULL

A	NULL
,	NULL
dysplastic	NULL
melanocytic	NULL
nevus	NULL
(	NULL
MM	NULL
precursor	NULL
le-sion	NULL
)	NULL
.	NULL

CD40	NULL
expression	NULL
(	NULL
red	NULL
staining	NULL
)	NULL
on	NULL
nevus	NULL
cells	NULL
in	NULL
the	NULL
dermis	NULL
and	NULL
epidermis	NULL
is	NULL
shown	NULL
(	NULL
arrows	NULL
;	NULL
magnification	NULL
,	NULL
X100	NULL
)	NULL
.	NULL

B	NULL
,	NULL
primary	NULL
tumor	NULL
of	NULL
MM	NULL
(	NULL
Clark	NULL
level	NULL
IV	NULL
,	NULL
4-mm	NULL
vertical	NULL
tumor	NULL
thickness	NULL
)	NULL
.	NULL

CD40	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
RESULTS	NULL
CD40	NULL
Expression	NULL
by	NULL
Human	NULL
Melanoma	NULL
Cells	NULL
in	NULL
Site	NULL
and	NULL
by	NULL
Melanoma	NULL
Cell	NULL
Lines	NULL
in	NULL
Vitro	NULL
.	NULL

Immunohistology	NULL
of	NULL
eryosections	NULL
from	NULL
tumor	NULL
specimen	NULL
of	NULL
MM	NULL
precursor	NULL
lesions	NULL
as	NULL
well	NULL
as	NULL
of	NULL
established	NULL
MM	NULL
revealed	NULL
CD40	NULL
expression	NULL
by	NULL
the	NULL
tumor	NULL
cells	NULL
of	NULL
prema-lignant	NULL
dysplastic	NULL
nevi	NULL
;	NULL
however	NULL
,	NULL
no	NULL
CD40	NULL
could	NULL
be	NULL
detected	NULL
on	NULL
normal	NULL
epidermal	NULL
melanocytes	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
strong	NULL
surface	NULL
expression	NULL
of	NULL
CD40	NULL
on	NULL
melanoma	NULL
cells	NULL
within	NULL
all	NULL
specimens	NULL
of	NULL
primary	NULL
tumors	NULL
of	NULL
melanoma	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
MM	NULL
metastases	NULL
,	NULL
CD40	NULL
staining	NULL
on	NULL
the	NULL
tumor	NULL
cells	NULL
was	NULL
weak	NULL
or	NULL
absent	NULL
,	NULL
whereas	NULL
the	NULL
expression	NULL
on	NULL
tumor	NULL
cells	NULL
(	NULL
arrows	NULL
)	NULL
and	NULL
intratumoral	NULL
endothelial	NULL
cells	NULL
(	NULL
arrowheads	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

Normal	NULL
MMI	NULL
melanocytes	NULL
at	NULL
the	NULL
dermo-epidermal	NULL
junction	NULL
(	NULL
***	NULL
*	NULL
*	NULL
)	NULL
MIRW	NULL
LB39-Mel	NULL
are	NULL
CD40	NULL
negative	NULL
(	NULL
magnification	NULL
,	NULL
X400	NULL
)	NULL
.	NULL

C	NULL
,	NULL
cuta-	NULL
l	NULL
L	NULL
neous	NULL
metastasis	NULL
of	NULL
MM	NULL
.	NULL

CD40	NULL
expression	NULL
on	NULL
tumor	NULL
IiG—C	NULL
trl	NULL
.	NULL

E	NULL
:	NULL
trl	NULL
.	NULL

Ig_G	NULL
»	NULL
C	NULL
166	NULL
cells	NULL
was	NULL
weak	NULL
or	NULL
absent	NULL
,	NULL
but	NULL
CD40	NULL
expression	NULL
by	NULL
€D40	NULL
CD40	NULL
CD40	NULL
intratumoral	NULL
endothelial	NULL
cells	NULL
was	NULL
strong	NULL
(	NULL
arrows	NULL
;	NULL
magnification	NULL
,	NULL
X400	NULL
)	NULL
.	NULL

D	NULL
,	NULL
CD40	NULL
expression	NULL
by	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
FACS	NULL
analysis	NULL
shows	NULL
three	NULL
representative	NULL
of	NULL
seven	NULL
CD4O-positive	NULL
cell	NULL
lines	NULL
stained	NULL
with	NULL
mAb	NULL
G-28.5	NULL
(	NULL
===	NULL
)	NULL
or	NULL
control	NULL
IgG1	NULL
(	NULL
)	NULL
.	NULL

E	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
of	NULL
CD40	NULL
mRNA	NULL
in	NULL
the	NULL
human	NULL
melanoma	NULL
cell	NULL
line	NULL
MIRW	NULL
with	NULL
and	NULL
without	NULL
cytokine	NULL
stimulation	NULL
.	NULL

A	NULL
single	NULL
CD40-spe-cific	NULL
band	NULL
was	NULL
detected	NULL
(	NULL
1.3-1.4	NULL
kb	NULL
)	NULL
.	NULL

The	NULL
188	NULL
rRNA	NULL
#	NULL
counts	NULL
10	NULL
g	NULL
10°	NULL
Fluorescence	NULL
intensity	NULL
band	NULL
of	NULL
the	NULL
ethidium	NULL
bromide	NULL
staining	NULL
of	NULL
the	NULL
gel	NULL
is	NULL
shown	NULL
to	NULL
verify	NULL
equal	NULL
RNA	NULL
loading	NULL
.	NULL

Densitometric	NULL
analysis	NULL
confirms	NULL
that	NULL
constitutive	NULL
levels	NULL
of	NULL
CD40	NULL
mRNA	NULL
are	NULL
elevated	NULL
2-3-fold	NULL
after	NULL
the	NULL
indicated	NULL
periods	NULL
of	NULL
stimulation	NULL
with	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
or	NULL
TNF-a	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
but	NULL
not	NULL
IL-1	NULL
3	NULL
(	NULL
1000	NULL
units/ml	NULL
)	NULL
.	NULL

As	NULL
a	NULL
positive	NULL
control	NULL
,	NULL
Daudi	NULL
mRNA	NULL
(	NULL
DAUDT	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

cytokine	NULL
IL-18	NULL
time	NULL
(	NULL
h	NULL
)	NULL
8	NULL
24	NULL
48	NULL
1,3	NULL
-	NULL
1,4	NULL
kb	NULL
18S	NULL
rRNA	NULL
-3	NULL
.	NULL

lat	NULL
Densitometry	NULL
52	NULL
Teak	NULL
}	NULL
?	NULL

1289	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
MM	NULL
Stin11ulus	NULL
Stimulus	NULL
A	NULL
|	NULL
ics	NULL
B	NULL
C	NULL
[	NULL
mre	NULL
D	NULL
|emesr	NULL
Ctrl	NULL
,	NULL
L-cells	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

CD40	NULL
ligation	NULL
stimulates	NULL
the	NULL
release	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
by	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

LB39-Mel	NULL
cells	NULL
were	NULL
prestimulated	NULL
in	NULL
medium	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
(	NULL
24	NULL
h	NULL
,	NULL
CD40L	NULL
L-cells	NULL
200	NULL
units/ml	NULL
)	NULL
and	NULL
washed	NULL
twice	NULL
,	NULL
and	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
were	NULL
then	NULL
cocultured	NULL
on	NULL
monolayers	NULL
of	NULL
mitomycin	NULL
C-treated	NULL
CD40L	NULL
*	NULL
+	NULL
Ctrl	NULL
.	NULL

L-cells	NULL
L-cells	NULL
or	NULL
untransfected	NULL
controls	NULL
.	NULL

After	NULL
48	NULL
h	NULL
,	NULL
supernatants	NULL
were	NULL
harvested	NULL
and	NULL
analyzed	NULL
for	NULL
the	NULL
indicated	NULL
human	NULL
cytokines	NULL
by	NULL
specific	NULL
ELISA	NULL
.	NULL

Columns	NULL
,	NULL
means	NULL
of	NULL
triplicate	NULL
measurements	NULL
;	NULL
*	NULL
~	NULL
CDA40L	NULL
L-cells	NULL
bars	NULL
,	NULL
SD	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
MM	NULL
cell	NULL
lines	NULL
MIRW	NULL
,	NULL
LB373	NULL
,	NULL
and	NULL
MMI	NULL
stimulated	NULL
with	NULL
CD40L	NULL
*	NULL
L-cells	NULL
or	NULL
+	NULL
IFN-y	NULL
|	NULL
Ctrl	NULL
.	NULL

L-cells	NULL
with	NULL
sCD40L	NULL
,	NULL
except	NULL
that	NULL
MIRW	NULL
did	NULL
not	NULL
secrete	NULL
TNF-	NULL
«	NULL
or	NULL
GM-CSF	NULL
.	NULL

*	NULL
IFN	NULL
?	NULL

_|	NULL
CD40L	NULL
L-celts	NULL
U	NULL
T	NULL
T	NULL
I	NULL
T	NULL
T	NULL
U	NULL
T	NULL
T	NULL
-+-0	NULL
4	NULL
8	NULL
12	NULL
0	NULL
5	NULL
10	NULL
15	NULL
0	NULL
10	NULL
20	NULL
30	NULL
0	NULL
40	NULL
80	NULL
ug/ml	NULL
ng/ml	NULL
ng/ml	NULL
pg/ml	NULL
endothelial	NULL
cells	NULL
of	NULL
intratumoral	NULL
vessels	NULL
retained	NULL
their	NULL
strong	NULL
CD40	NULL
surface	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
.	NULL

In	NULL
aggregate	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
gradual	NULL
loss	NULL
of	NULL
CD40	NULL
surface	NULL
antigen	NULL
during	NULL
melanoma	NULL
progression	NULL
.	NULL

To	NULL
confirm	NULL
and	NULL
extend	NULL
these	NULL
results	NULL
,	NULL
cultured	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
examined	NULL
for	NULL
surface	NULL
expression	NULL
of	NULL
CD40	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Staining	NULL
of	NULL
melanoma	NULL
cell	NULL
lines	NULL
with	NULL
the	NULL
CD4O0-specific	NULL
antibodies	NULL
G28.5	NULL
and	NULL
EA-5	NULL
revealed	NULL
7	NULL
of	NULL
18	NULL
to	NULL
be	NULL
CD40	NULL
positive	NULL
.	NULL

Fig	NULL
.	NULL

1D	NULL
shows	NULL
three	NULL
representative	NULL
cell	NULL
lines	NULL
positive	NULL
for	NULL
the	NULL
CD40	NULL
antigen	NULL
.	NULL

Interest-ingly	NULL
,	NULL
2	NULL
of	NULL
7	NULL
CD4O-positive	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
from	NULL
highly	NULL
immunogenic	NULL
melanomas	NULL
,	NULL
whereas	NULL
the	NULL
other	NULL
CD40	NULL
positive	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
from	NULL
MM	NULL
metastases	NULL
,	NULL
characterized	NULL
by	NULL
slow	NULL
local	NULL
tumor	NULL
growth	NULL
and	NULL
low	NULL
metastatic	NULL
potential	NULL
in	NULL
nu/nu	NULL
mice	NULL
(	NULL
23	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
all	NULL
CD4O0-negative	NULL
MM	NULL
cell	NULL
lines	NULL
were	NULL
established	NULL
from	NULL
rapidly	NULL
growing	NULL
advanced	NULL
stages	NULL
of	NULL
melanoma	NULL
me-tastases	NULL
.	NULL

IFN-y	NULL
was	NULL
shown	NULL
to	NULL
up-regulate	NULL
CD40	NULL
expression	NULL
on	NULL
cultured	NULL
human	NULL
keratinocytes	NULL
,	NULL
thymic	NULL
epithelial	NULL
cells	NULL
,	NULL
and	NULL
vascular	NULL
endothelial	NULL
cells	NULL
,	NULL
whereas	NULL
TNF-a	NULL
and	NULL
IL-1B	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
these	NULL
cytokines	NULL
modulate	NULL
the	NULL
level	NULL
of	NULL
CD40	NULL
on	NULL
MM	NULL
,	NULL
flow	NULL
cytometry	NULL
was	NULL
performed	NULL
after	NULL
IFN-y	NULL
,	NULL
TNF-	NULL
«	NULL
,	NULL
IL-1	NULL
,	NULL
and	NULL
CD40	NULL
stimulation	NULL
.	NULL

A	NULL
48-h	NULL
treatment	NULL
with	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
or	NULL
TNF-a	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

led	NULL
to	NULL
a	NULL
2-fold	NULL
increase	NULL
in	NULL
the	NULL
MFI	NULL
of	NULL
CD40	NULL
surface	NULL
staining	NULL
,	NULL
whereas	NULL
IL-1	NULL
(	NULL
1000	NULL
units/ml	NULL
,	NULL
48	NULL
h	NULL
)	NULL
or	NULL
CD40	NULL
triggering	NULL
(	NULL
CD40	NULL
*	NULL
L-cells	NULL
or	NULL
sCD4O0L	NULL
)	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Table	NULL
1	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
none	NULL
of	NULL
these	NULL
treatments	NULL
could	NULL
induce	NULL
CD40	NULL
expression	NULL
in	NULL
CD40	NULL
negative	NULL
MM	NULL
cell	NULL
lines	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

A	NULL
weak	NULL
CD40	NULL
surface	NULL
expression	NULL
was	NULL
also	NULL
observed	NULL
on	NULL
3	NULL
of	NULL
3	NULL
human	NULL
melanocyte	NULL
cell	NULL
lines	NULL
cultured	NULL
in	NULL
melanocyte	NULL
growth	NULL
medium	NULL
containing	NULL
insulin	NULL
and	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD40	NULL
mRNA	NULL
levels	NULL
were	NULL
determined	NULL
in	NULL
human	NULL
MM	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
.	NULL

A	NULL
single	NULL
1.3-1.4-kb	NULL
mRNA	NULL
transcript	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
MM	NULL
cell	NULL
line	NULL
MIRW	NULL
(	NULL
Fig	NULL
.	NULL

1£	NULL
)	NULL
,	NULL
corresponding	NULL
to	NULL
the	NULL
CD40	NULL
mRNA	NULL
transcript	NULL
described	NULL
for	NULL
human	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
MM	NULL
cell	NULL
line	NULL
HS294T	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
MIRW	NULL
with	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
!	NULL
)	NULL

or	NULL
TNF-a	NULL
(	NULL
50	NULL
Table	NULL
1	NULL
Cytokine-mediated	NULL
regulation	NULL
of	NULL
CD40	NULL
expression	NULL
on	NULL
human	NULL
melanoma	NULL
cells	NULL
``	NULL
Stimulation	NULL
CD40	NULL
expression	NULL
(	NULL
cMFI	NULL
)	NULL
Medium	NULL
44	NULL
35	NULL
50	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
89	NULL
75	NULL
95	NULL
TNF-a	NULL
(	NULL
50	NULL
ng/ml	NULL
)	NULL
82	NULL
69	NULL
88	NULL
MM	NULL
cell	NULL
lines	NULL
LB39-Mel	NULL
MIRW	NULL
MMI	NULL
``	NULL
Human	NULL
melanoma	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
cytokines	NULL
for	NULL
48	NULL
h.	NULL
MFIs	NULL
of	NULL
CD40	NULL
expression	NULL
levels	NULL
were	NULL
determined	NULL
by	NULL
FACS	NULL
analysis	NULL
after	NULL
staining	NULL
with	NULL
the	NULL
CD4O-specific	NULL
mAb	NULL
G-28.5	NULL
or	NULL
IgG	NULL
control	NULL
antibody	NULL
.	NULL

cMFI	NULL
was	NULL
calculated	NULL
by	NULL
subtraction	NULL
of	NULL
MFI	NULL
of	NULL
the	NULL
control	NULL
antibody	NULL
from	NULL
MFI	NULL
of	NULL
CD4O-specific	NULL
antibody	NULL
staining	NULL
,	NULL
as	NULL
detailed	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

One	NULL
representative	NULL
experiment	NULL
of	NULL
three	NULL
performed	NULL
is	NULL
shown	NULL
.	NULL

ng/ml	NULL
)	NULL
resulted	NULL
in	NULL
a	NULL
2-3-fold	NULL
induction	NULL
of	NULL
CD40	NULL
transcription	NULL
levels	NULL
as	NULL
early	NULL
as	NULL
8	NULL
h	NULL
after	NULL
cytokine	NULL
addition	NULL
(	NULL
Fig	NULL
.	NULL

1€	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
IL-1B	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

Again	NULL
,	NULL
neither	NULL
IFN-y	NULL
nor	NULL
TNF-a	NULL
induced	NULL
CD40	NULL
RNA	NULL
transcription	NULL
in	NULL
MM	NULL
that	NULL
did	NULL
not	NULL
constitutively	NULL
express	NULL
CD40	NULL
antigen	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
IFN-y	NULL
and	NULL
TNF-a	NULL
induced	NULL
up-regulation	NULL
of	NULL
surface	NULL
CD40	NULL
expression	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
the	NULL
result	NULL
of	NULL
increased	NULL
CD40	NULL
mRNA	NULL
transcription	NULL
.	NULL

CD40	NULL
Stimulation	NULL
Induces	NULL
the	NULL
Release	NULL
of	NULL
Proinflammatory	NULL
Cytokines	NULL
by	NULL
Melanoma	NULL
Cells	NULL
.	NULL

It	NULL
has	NULL
been	NULL
reported	NULL
that	NULL
CD40	NULL
ligation	NULL
induces	NULL
the	NULL
secretion	NULL
of	NULL
cytokines	NULL
such	NULL
as	NULL
IL-8	NULL
and	NULL
IL-6	NULL
from	NULL
human	NULL
keratinocytes	NULL
,	NULL
fibroblasts	NULL
,	NULL
monocytes	NULL
,	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
dendritic	NULL
cells	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1-3	NULL
)	NULL
.	NULL

Because	NULL
MMs	NULL
are	NULL
capable	NULL
of	NULL
producing	NULL
IL-8	NULL
,	NULL
IL-6	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
GM-CSF	NULL
among	NULL
other	NULL
T-cell	NULL
chemotactic	NULL
or	NULL
T	NULL
cell-activating	NULL
cytokines	NULL
(	NULL
15	NULL
,	NULL
25	NULL
)	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
CD40	NULL
ligation	NULL
on	NULL
cytokine	NULL
secretion	NULL
by	NULL
the	NULL
human	NULL
MM	NULL
cell	NULL
line	NULL
LB39-Mel	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

LB39-Mel	NULL
showed	NULL
no	NULL
constitutive	NULL
expression	NULL
of	NULL
IL-8	NULL
or	NULL
IL-6	NULL
and	NULL
only	NULL
low	NULL
basal	NULL
levels	NULL
of	NULL
GM-CSF	NULL
and	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
none	NULL
of	NULL
these	NULL
cytokines	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
the	NULL
supernatants	NULL
of	NULL
CD40-transfected	NULL
or	NULL
control	NULL
L-cells	NULL
cultured	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

CD40L	NULL
*	NULL
L-cells	NULL
stimulated	NULL
LB39-Mel	NULL
to	NULL
secrete	NULL
high	NULL
levels	NULL
of	NULL
IL-8	NULL
and	NULL
IL-6	NULL
(	NULL
4	NULL
g/ml	NULL
and	NULL
3-4	NULL
ng/ml	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
whereas	NULL
control	NULL
L-cells	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

A	NULL
24-h	NULL
priming	NULL
of	NULL
LB39-Mel	NULL
with	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
prior	NULL
to	NULL
CD40	NULL
stimulation	NULL
had	NULL
a	NULL
additive	NULL
effect	NULL
resulting	NULL
in	NULL
a	NULL
2-fold	NULL
increase	NULL
in	NULL
IL-8	NULL
and	NULL
IL-6	NULL
secretion	NULL
(	NULL
8	NULL
ug/ml	NULL
and	NULL
10-12	NULL
ng/ml	NULL
;	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
CD40L	NULL
*	NULL
L-cells	NULL
stimulated	NULL
the	NULL
production	NULL
of	NULL
TNF-a	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
Fig	NULL
.	NULL

2D	NULL
)	NULL
.	NULL

This	NULL
CD40-induced	NULL
TNF-a	NULL
(	NULL
7-8	NULL
ng/ml	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
30	NULL
pg/ml	NULL
!	NULL
)	NULL

secretion	NULL
was	NULL
further	NULL
enhanced	NULL
(	NULL
TNF-a	NULL
,	NULL
20	NULL
ng/ml	NULL
;	NULL
GM-CSF	NULL
60	NULL
pg/m	NULL
!	NULL

l	NULL
)	NULL
by	NULL
IFN-y	NULL
priming	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
C	NULL
and	NULL
D	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
LB373	NULL
,	NULL
MM1	NULL
,	NULL
and	NULL
MIRW	NULL
stimulated	NULL
with	NULL
CD40L	NULL
*	NULL
L-cells	NULL
and	NULL
MIRW	NULL
or	NULL
LB39-Mel	NULL
stimulated	NULL
with	NULL
sCD4OL	NULL
,	NULL
except	NULL
that	NULL
GM-CSF	NULL
and	NULL
TNF-a	NULL
were	NULL
not	NULL
detectable	NULL
in	NULL
MIRW	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
IFN-y	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
basal	NULL
production	NULL
of	NULL
IL-8	NULL
,	NULL
IL-6	NULL
,	NULL
TNF-a	NULL
@	NULL
,	NULL
or	NULL
GM-CSF	NULL
in	NULL
any	NULL
of	NULL
the	NULL
MM	NULL
cell	NULL
lines	NULL
studied	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
CD40	NULL
ligation	NULL
stimulates	NULL
specifically	NULL
the	NULL
release	NULL
of	NULL
the	NULL
proinflammatory	NULL
cytokines	NULL
IL-8	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
,	NULL
in	NULL
some	NULL
cases	NULL
,	NULL
TNF-a	NULL
and	NULL
GM-CSF	NULL
from	NULL
CD40-positive	NULL
human	NULL
melanoma	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
production	NULL
of	NULL
other	NULL
cytokines/growth	NULL
factors	NULL
such	NULL
as	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
,	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-1	NULL
B	NULL
is	NULL
not	NULL
affected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD40-mediated	NULL
Signals	NULL
Lead	NULL
to	NULL
Activation	NULL
of	NULL
the	NULL
Transcription	NULL
Factor	NULL
NF-KB	NULL
in	NULL
Human	NULL
Melanoma	NULL
Cells	NULL
.	NULL

There	NULL
is	NULL
evidence	NULL
that	NULL
CD40	NULL
ligation	NULL
results	NULL
in	NULL
the	NULL
mobilization	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
(	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Because	NULL
transcription	NULL
of	NULL
the	NULL
genes	NULL
of	NULL
1290	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
MIRW	NULL
60	NULL
min	NULL
.	NULL

2	NULL
3	NULL
4	NULL
LB39-Mel	NULL
!	NULL

30	NULL
min	NULL
.	NULL

1	NULL
}	NULL
2	NULL
3	NULL
4	NULL
``	NULL
anﬁ	NULL
«	NULL
®	NULL
®	NULL
<	NULL
0	NULL
&	NULL
&	NULL
&	NULL
d	NULL
a	NULL
-	NULL
«	NULL
-	NULL
#	NULL
&	NULL
Ue	NULL
4	NULL
a	NULL
#	NULL
30	NULL
min	NULL
.	NULL

2	NULL
3	NULL
4	NULL
60	NULL
min	NULL
.	NULL

2	NULL
3	NULL
4	NULL
]	NULL
1	NULL
O	NULL
4	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
CD40	NULL
ligation	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
in	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

LB39-Mel	NULL
and	NULL
MIRW	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
Lanes	NULL
7	NULL
)	NULL
or	NULL
stimulated	NULL
for	NULL
the	NULL
indicated	NULL
periods	NULL
with	NULL
TNF-	NULL
@	NULL
(	NULL
50	NULL
ng/ml	NULL
;	NULL
Lanes	NULL
2	NULL
)	NULL
,	NULL
sCD40L	NULL
(	NULL
Lanes	NULL
3	NULL
)	NULL
,	NULL
and	NULL
sCD4OL	NULL
preincubated	NULL
with	NULL
the	NULL
anti-CD40L	NULL
mAb	NULL
TRAP	NULL
(	NULL
10	NULL
ug/ml	NULL
;	NULL
Lanes	NULL
4	NULL
)	NULL
.	NULL

Total	NULL
extracts	NULL
of	NULL
10°	NULL
cells	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
for	NULL
NF-KB	NULL
binding	NULL
by	NULL
EMSA	NULL
.	NULL

Filled	NULL
arrowhead	NULL
,	NULL
position	NULL
of	NULL
NF-kB	NULL
DNA	NULL
complexes	NULL
;	NULL
O	NULL
,	NULL
nonspecific	NULL
binding	NULL
of	NULL
the	NULL
probe	NULL
;	NULL
open	NULL
arrowhead	NULL
,	NULL
unbound	NULL
oligonucleotide	NULL
.	NULL

all	NULL
cytokines	NULL
and	NULL
surface	NULL
molecules	NULL
we	NULL
found	NULL
up-regulated	NULL
in	NULL
CD40-triggered	NULL
MM	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
by	NULL
NF-KB	NULL
(	NULL
16	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
NF-KB	NULL
is	NULL
activated	NULL
by	NULL
CD40	NULL
signals	NULL
in	NULL
human	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

CD40	NULL
ligation	NULL
on	NULL
LB39-Mel	NULL
and	NULL
MIRW	NULL
led	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-B	NULL
,	NULL
as	NULL
detected	NULL
by	NULL
EMSA	NULL
30	NULL
min	NULL
and	NULL
1	NULL
h	NULL
after	NULL
stimulation	NULL
with	NULL
sCD40L	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
Lanes	NULL
3	NULL
)	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
inhibited	NULL
completely	NULL
by	NULL
preincubation	NULL
of	NULL
sCD40L	NULL
with	NULL
an	NULL
anti-CD40L	NULL
mAb	NULL
(	NULL
TRAP	NULL
,	NULL
10	NULL
ug/	NULL
ml	NULL
)	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
Lanes	NULL
4	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
MM	NULL
cells	NULL
with	NULL
TNF-a	NULL
(	NULL
50	NULL
ng/ml	NULL
;	NULL
Ref	NULL
.	NULL

28	NULL
)	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
Lanes	NULL
2	NULL
)	NULL
.	NULL

CD40	NULL
Ligation	NULL
Up-Regulates	NULL
Immunorelevant	NULL
Surface	NULL
Molecules	NULL
on	NULL
Melanoma	NULL
Cells	NULL
.	NULL

APC	NULL
triggering	NULL
of	NULL
CD40	NULL
by	NULL
CD4OL	NULL
leads	NULL
to	NULL
the	NULL
up-regulation	NULL
of	NULL
molecules	NULL
involved	NULL
in	NULL
T-cell	NULL
adhesion	NULL
,	NULL
antigen	NULL
presentation	NULL
,	NULL
and	NULL
activation	NULL
,	NULL
such	NULL
as	NULL
ICAM-1	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
II	NULL
molecules	NULL
,	NULL
costimulatory	NULL
molecules	NULL
of	NULL
the	NULL
B7	NULL
family	NULL
,	NULL
and	NULL
CD40	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

Because	NULL
MM	NULL
cells	NULL
are	NULL
also	NULL
capable	NULL
of	NULL
expressing	NULL
some	NULL
of	NULL
these	NULL
molecules	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
CD40	NULL
ligation	NULL
on	NULL
their	NULL
expression	NULL
of	NULL
ICAM-1	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
II	NULL
,	NULL
B7-1	NULL
,	NULL
B7-2	NULL
,	NULL
CD95	NULL
,	NULL
CD95L	NULL
,	NULL
CD44	NULL
,	NULL
CD4O0L	NULL
,	NULL
and	NULL
CD40	NULL
by	NULL
FACS	NULL
.	NULL

MM	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
primed	NULL
with	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
,	NULL
24	NULL
h	NULL
)	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
48	NULL
h	NULL
with	NULL
sCD4O0L	NULL
,	NULL
preincubated	NULL
with	NULL
the	NULL
blocking	NULL
mAb	NULL
39-1.106	NULL
or	NULL
appropriate	NULL
isotype	NULL
control	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

MIRW	NULL
constitutively	NULL
expressed	NULL
low	NULL
level	NULL
of	NULL
surface	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
cMFI	NULL
=	NULL
80	NULL
;	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

MIRW	NULL
stimulated	NULL
with	NULL
sCD4OL	NULL
without	NULL
IFN-y	NULL
priming	NULL
showed	NULL
only	NULL
a	NULL
weak	NULL
up-regulation	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
(	NULL
¢cMFI	NULL
=	NULL
100	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
after	NULL
IFN-y	NULL
priming	NULL
,	NULL
CD40	NULL
stimulation	NULL
induced	NULL
a	NULL
2-fold	NULL
up-regulation	NULL
(	NULL
¢MFI	NULL
=	NULL
240	NULL
)	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
compared	NULL
to	NULL
MIRW	NULL
primed	NULL
with	NULL
IFN-y	NULL
alone	NULL
(	NULL
cMFI	NULL
=	NULL
115	NULL
;	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

The	NULL
expression	NULL
level	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
on	NULL
MIRW	NULL
melanoma	NULL
cells	NULL
was	NULL
affected	NULL
analogously	NULL
by	NULL
CD40	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

The	NULL
cMFI	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
was	NULL
elevated	NULL
1.5-fold	NULL
after	NULL
the	NULL
combined	NULL
IFN-y/CD40	NULL
stimulation	NULL
(	NULL
¢MFI	NULL
=	NULL
68	NULL
)	NULL
,	NULL
compared	NULL
to	NULL
IFN-y	NULL
priming	NULL
alone	NULL
(	NULL
cMFI	NULL
=	NULL
40	NULL
;	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
MIRW	NULL
did	NULL
not	NULL
express	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
as	NULL
detected	NULL
by	NULL
FACS	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Likewise	NULL
,	NULL
ICAM-1	NULL
levels	NULL
were	NULL
elevated	NULL
3-fold	NULL
after	NULL
IFN-y/CD40	NULL
stimulation	NULL
(	NULL
¢cMFI	NULL
=	NULL
700	NULL
)	NULL
,	NULL
compared	NULL
to	NULL
basal	NULL
levels	NULL
(	NULL
cMFI	NULL
=	NULL
180	NULL
;	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

An	NULL
enhanced	NULL
shedding	NULL
of	NULL
soluble	NULL
ICAM-1	NULL
paralleled	NULL
this	NULL
increase	NULL
in	NULL
surface	NULL
ICAM-1	NULL
expression	NULL
as	NULL
determined	NULL
by	NULL
specific	NULL
ELISA	NULL
(	NULL
Fig	NULL
.	NULL

4D	NULL
)	NULL
.	NULL

All	NULL
effects	NULL
were	NULL
specific	NULL
for	NULL
CD40	NULL
because	NULL
they	NULL
were	NULL
reduced	NULL
or	NULL
inhibited	NULL
by	NULL
preincubation	NULL
of	NULL
sCD40L	NULL
with	NULL
the	NULL
anti-CD40L	NULL
mAb	NULL
39-1.106	NULL
but	NULL
not	NULL
with	NULL
an	NULL
isotype	NULL
control	NULL
mAb	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
observed	NULL
with	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
LB39-Mel	NULL
stimulated	NULL
with	NULL
sCD40L	NULL
or	NULL
with	NULL
CD4O0L	NULL
*	NULL
L-cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
no	NULL
CD4O0-mediated	NULL
alterations	NULL
in	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD95	NULL
,	NULL
CD95L	NULL
,	NULL
B7-1	NULL
,	NULL
B7-2	NULL
,	NULL
CD44	NULL
,	NULL
CD4O0L	NULL
,	NULL
or	NULL
CD40	NULL
could	NULL
be	NULL
detected	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD40	NULL
Stimulation	NULL
Enhances	NULL
Tumor-specific	NULL
CTL-mediated	NULL
Killing	NULL
of	NULL
Melanoma	NULL
Cells	NULL
.	NULL

Recently	NULL
it	NULL
has	NULL
been	NULL
demonstrated	NULL
that	NULL
CD40/CD4O0L-mediated	NULL
signals	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
CTLs	NULL
(	NULL
4-8	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
CTLs	NULL
recognize	NULL
melanoma-specific	NULL
antigens	NULL
in	NULL
a	NULL
MHC	NULL
class	NULL
I-restricted	NULL
fashion	NULL
,	NULL
and	NULL
the	NULL
expression	NULL
levels	NULL
of	NULL
ICAM-1	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
are	NULL
crucial	NULL
for	NULL
adhesion	NULL
,	NULL
recognition	NULL
,	NULL
and	NULL
lysis	NULL
of	NULL
target	NULL
cells	NULL
by	NULL
CD8	NULL
*	NULL
CTLs	NULL
(	NULL
29	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
investigated	NULL
whether	NULL
the	NULL
CD40	NULL
mediated	NULL
up-regulation	NULL
of	NULL
these	NULL
molecules	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
affects	NULL
melanoma	NULL
cell	NULL
lysis	NULL
by	NULL
CD8	NULL
*	NULL
CTLs	NULL
.	NULL

Cytotoxicity	NULL
assays	NULL
were	NULL
performed	NULL
using	NULL
as	NULL
targets	NULL
the	NULL
HLA-A2*	NULL
MelanA/MART-1~*	NULL
human	NULL
melanoma	NULL
cell	NULL
line	NULL
LB39-Mel	NULL
stimulated	NULL
with	NULL
CD40+*	NULL
L-cells	NULL
or	NULL
control	NULL
L-cells	NULL
.	NULL

The	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
clone	NULL
LB373-CTL-246/15	NULL
,	NULL
recognizing	NULL
the	NULL
MelanA/MART1	NULL
peptide	NULL
27-35	NULL
in	NULL
a	NULL
HLA-AZ-restricted	NULL
s	NULL
fox	NULL
)	NULL
_	NULL
c	NULL
fea	NULL
)	NULL
_	NULL
o	NULL
(	NULL
om	NULL
HLA-ABC	NULL
J	NULL
>	NULL
Stirr11u|us	NULL
Stimulus	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

CD40	NULL
triggering	NULL
up-regulates	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
II	NULL
and	NULL
ICAM-1	NULL
on	NULL
human	NULL
melanoma	NULL
cells	NULL
.	NULL

The	NULL
.	NULL

,	NULL
melanoma	NULL
cell	NULL
line	NULL
MIRW	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
priming	NULL
(	NULL
24	NULL
medium	NULL
medium	NULL
h	NULL
,	NULL
200	NULL
units/ml	NULL
)	NULL
was	NULL
stimulated	NULL
with	NULL
sCD40L	NULL
,	NULL
sCD40L	NULL
pre-	NULL
.	NULL

incubated	NULL
with	NULL
the	NULL
anti-CD40L	NULL
mAb	NULL
39-1.106	NULL
or	NULL
control	NULL
mAb	NULL
medium	NULL
sCD40L	NULL
+ct-1gG	NULL
(	NULL
10	NULL
g/ml	NULL
)	NULL
,	NULL
or	NULL
medium	NULL
alone	NULL
for	NULL
48	NULL
h.	NULL
MM	NULL
cells	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
FACS	NULL
for	NULL
MHC	NULL
class	NULL
I	NULL
(	NULL
A	NULL
)	NULL
,	NULL
MHC	NULL
class	NULL
II	NULL
(	NULL
B	NULL
)	NULL
,	NULL
and	NULL
medium	NULL
-|	NULL
sCD40L+-CD40L	NULL
ICAM-1	NULL
(	NULL
C	NULL
)	NULL
surface	NULL
expression	NULL
.	NULL

MFIs	NULL
of	NULL
surface	NULL
expression	NULL
levels	NULL
corrected	NULL
for	NULL
background	NULL
staining	NULL
of	NULL
an	NULL
appropriate	NULL
control	NULL
mAb	NULL
(	NULL
cMFI	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

The	NULL
level	NULL
of	NULL
soluble	NULL
ICAM-1	NULL
IFNy	NULL
medium	NULL
(	NULL
D	NULL
)	NULL
was	NULL
determined	NULL
by	NULL
specific	NULL
ELISA	NULL
.	NULL

A	NULL
representative	NULL
ex	NULL
periment	NULL
of	NULL
three	NULL
is	NULL
shown	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
IFNy	NULL
|	NULL
sCD4O0L	NULL
+ctr-igG	NULL
LB39-Mel	NULL
and	NULL
MMI	NULL
stimulated	NULL
either	NULL
with	NULL
CD40L	NULL
L-cells	NULL
or	NULL
sCD40L	NULL
.	NULL

Columns	NULL
,	NULL
means	NULL
of	NULL
triplicate	NULL
measurements	NULL
;	NULL
IFN-y	NULL
sCD40L	NULL
+	NULL
@	NULL
-CDA40L	NULL
bars	NULL
,	NULL
SD	NULL
.	NULL

I	NULL
I	NULL
I	NULL
U	NULL
I	NULL
I	NULL
|	NULL
povo	NULL
|	NULL
I	NULL
E	NULL
U	NULL
100	NULL
200	NULL
300	NULL
0	NULL
20	NULL
40	NULL
60	NULL
80	NULL
0	NULL
250	NULL
500	NULL
750	NULL
0	NULL
56	NULL
10	NULL
cMFI	NULL
cMF	NULL
]	NULL
cMFI	NULL
ng/ml	NULL
o	NULL
1291	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
A	NULL
B	NULL
40	NULL
40	NULL
0	NULL
I	NULL
@	NULL
|	NULL
@	NULL
{	NULL
|	NULL
E	NULL
30	NULL
-	NULL
30	NULL
{	NULL
[	NULL
=	NULL
3	NULL
1	NULL
5	NULL
20	NULL
1	NULL
20	NULL
E	NULL
4	NULL
J	NULL
o	NULL
]	NULL
]	NULL
$	NULL
10	NULL
7	NULL
10	NULL
{	NULL
%	NULL
o.	NULL
a	NULL
1	NULL
]	NULL
x	NULL
]	NULL
1	NULL
0	NULL
T	NULL
T	NULL
T	NULL
0	NULL
+-	NULL
t	NULL
t	NULL
1710	NULL
31	NULL
101	NULL
1171	NULL
371	NULL
101	NULL
Effector	NULL
:	NULL
Target	NULL
Ratio	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

CD4O-triggering	NULL
enhances	NULL
tumor	NULL
antigen	NULL
specific	NULL
CTL-lysis	NULL
of	NULL
human	NULL
melanoma	NULL
.	NULL

Specific	NULL
lysis	NULL
of	NULL
CD40	NULL
stimulated	NULL
LB39-Mel	NULL
MM	NULL
cells	NULL
(	NULL
HLA-A2*	NULL
,	NULL
MelanA/	NULL
MART1*	NULL
)	NULL
by	NULL
anti-MelanA/MART1	NULL
(	NULL
peptide	NULL
27-35	NULL
)	NULL
specific	NULL
CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
is	NULL
shown	NULL
.	NULL

'Cr-labeled	NULL
targets	NULL
were	NULL
incubated	NULL
with	NULL
LB373-CTL-246/15	NULL
at	NULL
the	NULL
indicated	NULL
E	NULL
:	NULL
T	NULL
ratios	NULL
.	NULL

Chromium	NULL
release	NULL
was	NULL
measured	NULL
after	NULL
4	NULL
h	NULL
,	NULL
and	NULL
the	NULL
percentage	NULL
of	NULL
specific	NULL
lysis	NULL
was	NULL
calculated	NULL
as	NULL
described	NULL
in	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

A	NULL
,	NULL
lysis	NULL
of	NULL
chromium-labeled	NULL
T2	NULL
cells	NULL
by	NULL
LB373-CTL-246/15	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
@	NULL
)	NULL
or	NULL
absence	NULL
(	NULL
O	NULL
)	NULL
of	NULL
the	NULL
MelanA/MART1	NULL
peptide	NULL
EAAGIGILTV	NULL
(	NULL
1	NULL
pm	NULL
)	NULL
.	NULL

B	NULL
,	NULL
lysis	NULL
of	NULL
LB39-Mel	NULL
melanoma	NULL
cells	NULL
with	NULL
(	NULL
@	NULL
)	NULL
or	NULL
without	NULL
(	NULL
O	NULL
)	NULL
IFN-y	NULL
priming	NULL
(	NULL
200	NULL
units/ml/24	NULL
h	NULL
)	NULL
or	NULL
LB39-Mel	NULL
melanoma	NULL
cells	NULL
primed	NULL
with	NULL
IFN-y	NULL
followed	NULL
by	NULL
a	NULL
48-h	NULL
coculture	NULL
with	NULL
irradiated	NULL
L-cells	NULL
either	NULL
CD40L-transfected	NULL
(	NULL
BBI	NULL
)	NULL
or	NULL
control	NULL
(	NULL
]	NULL
)	NULL
.	NULL

Data	NULL
points	NULL
,	NULL
means	NULL
of	NULL
triplicate	NULL
cultures	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
of	NULL
two	NULL
performed	NULL
.	NULL

fashion	NULL
was	NULL
used	NULL
as	NULL
the	NULL
effector	NULL
population	NULL
.	NULL

Peptide	NULL
specificity	NULL
of	NULL
CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
was	NULL
confirmed	NULL
using	NULL
HLA-A2+*	NULL
T2	NULL
target	NULL
cells	NULL
pulsed	NULL
with	NULL
1	NULL
um	NULL
MelanA/MART-1	NULL
peptide	NULL
27-35	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
closed	NULL
circles	NULL
)	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
open	NULL
circles	NULL
)	NULL
.	NULL

Impor-tantly	NULL
,	NULL
CD40	NULL
ligation	NULL
following	NULL
IFN-y	NULL
priming	NULL
markedly	NULL
enhanced	NULL
the	NULL
susceptibility	NULL
of	NULL
LB39-Mel	NULL
melanoma	NULL
cells	NULL
to	NULL
specific	NULL
lysis	NULL
by	NULL
CTL	NULL
clone	NULL
LB373-CTL-246/15	NULL
(	NULL
28	NULL
%	NULL
specific	NULL
lysis	NULL
;	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
closed	NULL
squares	NULL
)	NULL
as	NULL
compared	NULL
to	NULL
unstimulated	NULL
MM	NULL
(	NULL
12	NULL
%	NULL
specific	NULL
lysis	NULL
;	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
open	NULL
circles	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
LB39-Mel	NULL
with	NULL
IFN-y	NULL
alone	NULL
(	NULL
16	NULL
%	NULL
specific	NULL
lysis	NULL
;	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
open	NULL
squares	NULL
)	NULL
or	NULL
CD40	NULL
*L	NULL
L-cells	NULL
alone	NULL
(	NULL
17	NULL
%	NULL
specific	NULL
lysis	NULL
;	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
closed	NULL
squares	NULL
)	NULL
had	NULL
only	NULL
minor	NULL
effects	NULL
on	NULL
CTL	NULL
lysis	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
with	NULL
LB39-Mel	NULL
stimulated	NULL
with	NULL
sCD40L	NULL
or	NULL
CD40*L	NULL
L-cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
CD40	NULL
ligation	NULL
on	NULL
human	NULL
melanoma	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
augmenting	NULL
tumor	NULL
lysis	NULL
mediated	NULL
by	NULL
CD8	NULL
*	NULL
CTL	NULL
specific	NULL
for	NULL
melanoma	NULL
antigens	NULL
presented	NULL
in	NULL
the	NULL
context	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
.	NULL

CD40	NULL
Ligation	NULL
Induces	NULL
Growth	NULL
Inhibition	NULL
and	NULL
Apoptosis	NULL
in	NULL
Human	NULL
Melanoma	NULL
Cells	NULL
.	NULL

Controversial	NULL
effects	NULL
of	NULL
CD40	NULL
triggering	NULL
on	NULL
the	NULL
growth	NULL
of	NULL
nontransformed	NULL
and	NULL
of	NULL
transformed	NULL
cells	NULL
have	NULL
been	NULL
described	NULL
.	NULL

Although	NULL
CD40	NULL
stimulation	NULL
of	NULL
normal	NULL
B	NULL
cells	NULL
leads	NULL
to	NULL
enhanced	NULL
cell	NULL
proliferation	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
,	NULL
growth	NULL
inhibition	NULL
and	NULL
apoptosis	NULL
are	NULL
observed	NULL
in	NULL
B	NULL
lymphoma	NULL
and	NULL
myeloma	NULL
(	NULL
11	NULL
,	NULL
30	NULL
,	NULL
31	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
CD4O0-mediated	NULL
effects	NULL
on	NULL
the	NULL
growth	NULL
and	NULL
survival	NULL
of	NULL
human	NULL
melanoma	NULL
cells	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
proliferation	NULL
and	NULL
viability	NULL
of	NULL
MM	NULL
cells	NULL
and	NULL
performed	NULL
DNA	NULL
fragmentation	NULL
assays	NULL
.	NULL

LB39-Me	NULL
!	NULL

,	NULL
either	NULL
untreated	NULL
or	NULL
primed	NULL
with	NULL
IFN-y	NULL
for	NULL
24	NULL
h	NULL
,	NULL
were	NULL
washed	NULL
extensively	NULL
,	NULL
seeded	NULL
at	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
in	NULL
six-well	NULL
plates	NULL
and	NULL
cultured	NULL
either	NULL
with	NULL
medium	NULL
alone	NULL
,	NULL
or	NULL
stimulated	NULL
with	NULL
medium	NULL
containing	NULL
sCD40L	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A-D	NULL
)	NULL
or	NULL
with	NULL
CD40L	NULL
L-cells	NULL
(	NULL
Fig	NULL
.	NULL

66	NULL
)	NULL
.	NULL

After	NULL
72	NULL
h	NULL
,	NULL
the	NULL
cultures	NULL
were	NULL
inspected	NULL
by	NULL
inverted	NULL
microscopy	NULL
and	NULL
photomicrographs	NULL
were	NULL
taken	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A-D	NULL
)	NULL
.	NULL

When	NULL
compared	NULL
to	NULL
LB39-Mel	NULL
cultured	NULL
in	NULL
medium	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
,	NULL
a	NULL
treatment	NULL
with	NULL
sCD40L	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
or	NULL
IFN-y	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
alone	NULL
had	NULL
only	NULL
moderate	NULL
effects	NULL
on	NULL
cell	NULL
density	NULL
and	NULL
cell	NULL
morphology	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
following	NULL
IFN-y	NULL
priming	NULL
,	NULL
sCD4OL	NULL
treatment	NULL
led	NULL
to	NULL
dramatic	NULL
decrease	NULL
in	NULL
density	NULL
and	NULL
numbers	NULL
of	NULL
MM	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6D	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
these	NULL
results	NULL
,	NULL
MM	NULL
cell	NULL
proliferation	NULL
was	NULL
assessed	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
(	NULL
Fig	NULL
.	NULL

6E	NULL
)	NULL
.	NULL

Forty-eight-h	NULL
coculture	NULL
of	NULL
LB39-Mel	NULL
with	NULL
mitomycin	NULL
C-treated	NULL
CD40L	NULL
*	NULL
L-cells	NULL
inhibited	NULL
cell	NULL
proliferation	NULL
by	NULL
50	NULL
%	NULL
,	NULL
as	NULL
compared	NULL
to	NULL
MM	NULL
cells	NULL
cocultured	NULL
with	NULL
nontransfected	NULL
L-cells	NULL
or	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

IFN-y	NULL
priming	NULL
further	NULL
increased	NULL
the	NULL
CD40	NULL
induced	NULL
inhibition	NULL
of	NULL
MM	NULL
proliferation	NULL
up	NULL
to	NULL
70	NULL
%	NULL
,	NULL
whereas	NULL
IFN-y	NULL
alone	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

Addition	NULL
of	NULL
either	NULL
sTNF-RI	NULL
(	NULL
0.5	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
which	NULL
effectively	NULL
neutralizes	NULL
the	NULL
activity	NULL
of	NULL
TNF-a	NULL
released	NULL
by	NULL
MM	NULL
,	NULL
or	NULL
of	NULL
APO1/Fas-immunoglobulin	NULL
(	NULL
20	NULL
ug/ml1	NULL
)	NULL
,	NULL
a	NULL
biologically	NULL
active	NULL
inhibitor	NULL
of	NULL
FasL	NULL
activity	NULL
,	NULL
did	NULL
not	NULL
influence	NULL
the	NULL
CD40-mediated	NULL
growth	NULL
inhibition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Similar	NULL
observations	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A-E	NULL
,	NULL
were	NULL
made	NULL
with	NULL
MIRW	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Inverted	NULL
microscopy	NULL
of	NULL
CD4O-stimulated	NULL
MM	NULL
also	NULL
revealed	NULL
morphological	NULL
changes	NULL
associated	NULL
with	NULL
apoptotic	NULL
cell	NULL
death-like	NULL
membrane	NULL
protrusion	NULL
(	NULL
Ref	NULL
.	NULL

32	NULL
;	NULL
Fig	NULL
.	NULL

6D	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
FACS	NULL
analysis	NULL
of	NULL
propidium	NULL
iodide-stained	NULL
MIRW	NULL
cells	NULL
,	NULL
cocultured	NULL
for	NULL
48	NULL
h	NULL
with	NULL
CD40L	NULL
*	NULL
L-cells	NULL
,	NULL
demonstrated	NULL
a	NULL
30	NULL
%	NULL
decrease	NULL
in	NULL
MM	NULL
cell	NULL
viability	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

IFN-y	NULL
priming	NULL
did	NULL
not	NULL
alter	NULL
this	NULL
effect	NULL
.	NULL

To	NULL
verify	NULL
whether	NULL
CD40	NULL
ligation	NULL
induces	NULL
apoptosis	NULL
in	NULL
MM	NULL
,	NULL
we	NULL
analyzed	NULL
DNA	NULL
preparations	NULL
by	NULL
agarose	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Fragmentation	NULL
of	NULL
DNA	NULL
was	NULL
observed	NULL
when	NULL
MIRW	NULL
were	NULL
CD40	NULL
stimulated	NULL
with	NULL
sCD4OL	NULL
for	NULL
48	NULL
h	NULL
,	NULL
either	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
priming	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
prestimulation	NULL
with	NULL
IFN-y	NULL
alone	NULL
or	NULL
culture	NULL
for	NULL
48	NULL
h	NULL
in	NULL
medium	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DNA	NULL
fragmentation	NULL
in	NULL
MM	NULL
cells	NULL
was	NULL
also	NULL
assessed	NULL
by	NULL
enzymatic	NULL
incorporation	NULL
of	NULL
fluorescein-labeled	NULL
dUTP	NULL
into	NULL
DNA	NULL
strand	NULL
breaks	NULL
and	NULL
subsequent	NULL
FACS	NULL
analysis	NULL
.	NULL

FITC-dUTP-labeled	NULL
DNA	NULL
was	NULL
detected	NULL
when	NULL
MIRW	NULL
were	NULL
cocultured	NULL
for	NULL
72	NULL
h	NULL
with	NULL
sCD4O0L	NULL
,	NULL
either	NULL
primed	NULL
with	NULL
IFN-y	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
Fig	NULL
.	NULL

6F	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
when	NULL
LB39-Mel	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
either	NULL
CD40L	NULL
*	NULL
L-cells	NULL
or	NULL
sCD40L	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
sTNF-RI	NULL
(	NULL
0,5	NULL
ug/ml	NULL
!	NULL
)	NULL

or	NULL
APO1/Fas-immunoglobulin	NULL
(	NULL
20	NULL
ug/ml	NULL
!	NULL
)	NULL

during	NULL
the	NULL
entire	NULL
period	NULL
of	NULL
CD4O0-stimulation	NULL
did	NULL
not	NULL
prevent	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

DISCUSSION	NULL
CD40	NULL
expression	NULL
on	NULL
human	NULL
melanoma	NULL
(	NULL
MM	NULL
)	NULL
was	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
,	NULL
but	NULL
little	NULL
was	NULL
known	NULL
about	NULL
its	NULL
biological	NULL
relevance	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
report	NULL
the	NULL
functional	NULL
expression	NULL
of	NULL
CD40	NULL
on	NULL
a	NULL
subset	NULL
of	NULL
MM	NULL
in	NULL
situ	NULL
as	NULL
well	NULL
as	NULL
by	NULL
some	NULL
MM	NULL
cell	NULL
lines	NULL
in	NULL
vitro	NULL
.	NULL

Specifically	NULL
,	NULL
we	NULL
demonstrate	NULL
a	NULL
gradual	NULL
loss	NULL
of	NULL
CD40	NULL
expression	NULL
during	NULL
melanoma	NULL
progression	NULL
in	NULL
situ	NULL
.	NULL

We	NULL
also	NULL
found	NULL
human	NULL
MM	NULL
cell	NULL
lines	NULL
established	NULL
from	NULL
immunogenic	NULL
MM	NULL
but	NULL
not	NULL
from	NULL
advanced-stage	NULL
metastatic	NULL
tissue	NULL
positive	NULL
for	NULL
the	NULL
CD40	NULL
antigen	NULL
,	NULL
thus	NULL
paralleling	NULL
the	NULL
down-regulation	NULL
of	NULL
CD40	NULL
expression	NULL
on	NULL
MM	NULL
metastases	NULL
in	NULL
situ	NULL
.	NULL

These	NULL
results	NULL
are	NULL
in	NULL
line	NULL
with	NULL
previous	NULL
reports	NULL
that	NULL
50	NULL
%	NULL
of	NULL
MM	NULL
cell	NULL
lines	NULL
generated	NULL
from	NULL
primary	NULL
tumors	NULL
,	NULL
but	NULL
only	NULL
a	NULL
minority	NULL
of	NULL
cell	NULL
lines	NULL
derived	NULL
from	NULL
metastases	NULL
express	NULL
CD40	NULL
(	NULL
18	NULL
)	NULL
.	NULL

In	NULL
CD4O0-positive	NULL
but	NULL
not	NULL
in	NULL
CD40-negative	NULL
MM	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
this	NULL
antigen	NULL
was	NULL
increased	NULL
after	NULL
stimulation	NULL
with	NULL
IFN-y	NULL
or	NULL
TNF-a	NULL
but	NULL
not	NULL
with	NULL
IL-1	NULL
or	NULL
CD4OL	NULL
.	NULL

By	NULL
FACS	NULL
analysis	NULL
,	NULL
we	NULL
found	NULL
none	NULL
of	NULL
the	NULL
MMs	NULL
positive	NULL
for	NULL
CD4O0L	NULL
(	NULL
CD154	NULL
)	NULL
using	NULL
two	NULL
different	NULL
antibodies	NULL
(	NULL
39-1.106	NULL
and	NULL
TRAP	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
can	NULL
not	NULL
support	NULL
the	NULL
theory	NULL
of	NULL
an	NULL
autocrine	NULL
CD40-CD40L	NULL
stimulation	NULL
loop	NULL
in	NULL
MM	NULL
,	NULL
as	NULL
suggested	NULL
by	NULL
van	NULL
den	NULL
Oord	NULL
et	NULL
al	NULL
.	NULL

(	NULL
17	NULL
)	NULL
.	NULL

Herein	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
CD40	NULL
on	NULL
human	NULL
MM	NULL
cells	NULL
is	NULL
functional	NULL
because	NULL
CD40	NULL
ligation	NULL
stimulates	NULL
their	NULL
release	NULL
of	NULL
the	NULL
proinflammatory	NULL
cytokines	NULL
IL-6	NULL
,	NULL
IL-8	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
TNF-	NULL
«	NULL
.	NULL

We	NULL
further	NULL
demonstrate	NULL
that	NULL
cross-linking	NULL
of	NULL
CD40	NULL
on	NULL
human	NULL
MM	NULL
up-regulates	NULL
their	NULL
surface	NULL
expression	NULL
of	NULL
ICAM-1	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
molecules	NULL
,	NULL
thus	NULL
paralleling	NULL
observations	NULL
made	NULL
in	NULL
APCs	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
APC	NULL
,	NULL
a	NULL
CD4O0-mediated	NULL
up-regulation	NULL
of	NULL
B7-1	NULL
,	NULL
B7-2	NULL
,	NULL
CD44	NULL
,	NULL
or	NULL
CD40	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

1	NULL
and	NULL
2	NULL
)	NULL
was	NULL
not	NULL
detected	NULL
.	NULL

Both	NULL
the	NULL
CD4O0-induced	NULL
cytokine	NULL
secretion	NULL
and	NULL
surface	NULL
1292	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
1	NULL
.	NULL

Stimulus	NULL
2	NULL
.	NULL

Stimulus	NULL
``	NULL
HJdThd	NULL
incorporation	NULL
(	NULL
cpm	NULL
+/-	NULL
SD	NULL
)	NULL
-	NULL
Medium	NULL
M	NULL
Ctrl	NULL
.	NULL

L-cells	NULL
*	NULL
CDA40L	NULL
L-cells	NULL
IFN-y	NULL
Medium	NULL
IFN-y	NULL
Ctrl	NULL
.	NULL

L-cells	NULL
IFN-y	NULL
CD40L	NULL
L-cells	NULL
#	NULL
Events	NULL
10°	NULL
0	NULL
20000	NULL
40000	NULL
IFN-y+sCD40L	NULL
IFN-y	NULL
+	NULL
medium	NULL
Fluorescence	NULL
intensity	NULL
molecule	NULL
expression	NULL
were	NULL
enhanced	NULL
by	NULL
IFN-y	NULL
priming	NULL
,	NULL
which	NULL
is	NULL
most	NULL
likely	NULL
due	NULL
to	NULL
the	NULL
IFN-y-mediated	NULL
up-regulation	NULL
of	NULL
CD40	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
some	NULL
CD4O-triggered	NULL
MM	NULL
cell	NULL
lines	NULL
release	NULL
substantial	NULL
amounts	NULL
of	NULL
IL-6	NULL
,	NULL
IL-8	NULL
(	NULL
MIRW	NULL
,	NULL
LB39-Mel	NULL
,	NULL
MMI	NULL
,	NULL
and	NULL
LB373	NULL
)	NULL
,	NULL
and	NULL
GM-CSF	NULL
and	NULL
TNF-a	NULL
(	NULL
LB39-Mel	NULL
,	NULL
MMI1	NULL
,	NULL
LB373	NULL
)	NULL
may	NULL
have	NULL
consequences	NULL
for	NULL
the	NULL
generation	NULL
of	NULL
MM-specific	NULL
immune	NULL
responses	NULL
.	NULL

For	NULL
example	NULL
,	NULL
murine	NULL
MMs	NULL
transfected	NULL
with	NULL
the	NULL
GM-CSF	NULL
or	NULL
IL-6	NULL
gene	NULL
form	NULL
significantly	NULL
smaller	NULL
tumors	NULL
and	NULL
are	NULL
more	NULL
likely	NULL
to	NULL
be	NULL
rejected	NULL
than	NULL
untransfected	NULL
controls	NULL
(	NULL
33-35	NULL
)	NULL
.	NULL

The	NULL
CD40-induced	NULL
secretion	NULL
of	NULL
IL-8	NULL
could	NULL
also	NULL
augment	NULL
the	NULL
interactions	NULL
of	NULL
MM	NULL
and	NULL
T	NULL
cells	NULL
because	NULL
a	NULL
major	NULL
biological	NULL
activity	NULL
of	NULL
IL-8	NULL
is	NULL
the	NULL
attraction	NULL
and	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
sites	NULL
of	NULL
specific	NULL
immune	NULL
responses	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
we	NULL
find	NULL
that	NULL
TNF-a	NULL
secretion	NULL
is	NULL
enhanced	NULL
in	NULL
some	NULL
CD40-stimulated	NULL
MMs	NULL
,	NULL
which	NULL
could	NULL
exert	NULL
direct	NULL
antineoplastic	NULL
effects	NULL
on	NULL
those	NULL
tumor	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
.	NULL

We	NULL
wanted	NULL
to	NULL
characterize	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
CD40	NULL
ligation	NULL
up-regulates	NULL
the	NULL
above	NULL
described	NULL
surface	NULL
molecules	NULL
and	NULL
cytokines	NULL
in	NULL
MM	NULL
.	NULL

Our	NULL
finding	NULL
that	NULL
CD40	NULL
signals	NULL
lead	NULL
to	NULL
NF-kB	NULL
mobilization	NULL
in	NULL
human	NULL
MM	NULL
suggests	NULL
that	NULL
the	NULL
CD4O0-induced	NULL
events	NULL
are	NULL
mediated	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
through	NULL
activated	NULL
NF-KB	NULL
,	NULL
as	NULL
has	NULL
been	NULL
shown	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
(	NULL
reviewed	NULL
in	NULL
Ref	NULL
.	NULL

16	NULL
)	NULL
.	NULL

Because	NULL
TNF-a	NULL
activates	NULL
NF-KB	NULL
(	NULL
16	NULL
)	NULL
and	NULL
up-regulates	NULL
the	NULL
expression	NULL
of	NULL
ICAM-1	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
and	NULL
distinct	NULL
cytokines	NULL
in	NULL
MM	NULL
(	NULL
38	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
these	NULL
CD4O0-induced	NULL
changes	NULL
are	NULL
due	NULL
to	NULL
TNF-a	NULL
released	NULL
from	NULL
CD4O0-triggered	NULL
MM	NULL
.	NULL

However	NULL
,	NULL
we	NULL
consider	NULL
this	NULL
possibility	NULL
unlikely	NULL
because	NULL
we	NULL
also	NULL
observed	NULL
a	NULL
CD40	NULL
stimulation	NULL
of	NULL
ICAM-1	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
II	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
IL-8	NULL
in	NULL
MIRW	NULL
cells	NULL
that	NULL
did	NULL
not	NULL
secrete	NULL
TNF-a	NULL
following	NULL
CD40	NULL
triggering	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
sTNF-RI	NULL
that	NULL
effectively	NULL
neutralizes	NULL
TNF-a	NULL
activity	NULL
did	NULL
not	NULL
block	NULL
the	NULL
CD4O0-triggered	NULL
response	NULL
in	NULL
MM	NULL
.	NULL

The	NULL
importance	NULL
of	NULL
CD40-CD4O0L	NULL
interactions	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
specific	NULL
CTL-effector	NULL
populations	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
(	NULL
4-7	NULL
,	NULL
9	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
CD40	NULL
cross-linking	NULL
leads	NULL
to	NULL
enhanced	NULL
lysis	NULL
of	NULL
a	NULL
HLA-A2*	NULL
and	NULL
MelanA/MART-1-expressing	NULL
melanoma	NULL
cell	NULL
line	NULL
by	NULL
a	NULL
MelanA/MART-1-peptide	NULL
specific	NULL
CTL	NULL
clone	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
level	NULL
of	NULL
surface	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
on	NULL
MM	NULL
is	NULL
crucial	NULL
for	NULL
their	NULL
recognition	NULL
by	NULL
specific	NULL
CTLs	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
CD40	NULL
triggering	NULL
up-regulates	NULL
MHC	NULL
class	NULL
I	NULL
molecules	NULL
on	NULL
MM	NULL
may	NULL
,	NULL
thus	NULL
,	NULL
explain	NULL
their	NULL
enhanced	NULL
susceptibility	NULL
to	NULL
specific	NULL
CTL-mediated	NULL
kill-ing	NULL
.	NULL

This	NULL
study	NULL
also	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
in	NULL
vivo	NULL
CD40L-positive	NULL
tumor-infiltrating	NULL
CD4	NULL
*	NULL
,	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
may	NULL
receive	NULL
essential	NULL
activation	NULL
signals	NULL
from	NULL
CD4O0-positive	NULL
MMs	NULL
(	NULL
4	NULL
,	NULL
40	NULL
,	NULL
41	NULL
)	NULL
.	NULL

Whether	NULL
the	NULL
secretion	NULL
of	NULL
soluble	NULL
ICAM-1	NULL
molecules	NULL
observed	NULL
after	NULL
CD40	NULL
stimulation	NULL
in	NULL
vitro	NULL
has	NULL
a	NULL
negative	NULL
impact	NULL
on	NULL
the	NULL
susceptibility	NULL
of	NULL
MM	NULL
to	NULL
CTL	NULL
lysis	NULL
in	NULL
vivo	NULL
(	NULL
42	NULL
,	NULL
43	NULL
)	NULL
remains	NULL
to	NULL
be	NULL
evaluated	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
study	NULL
demonstrates	NULL
that	NULL
CD40	NULL
ligation	NULL
inhibits	NULL
the	NULL
growth	NULL
and	NULL
subsequently	NULL
leads	NULL
to	NULL
apoptosis	NULL
of	NULL
MM	NULL
.	NULL

This	NULL
is	NULL
in	NULL
line	NULL
with	NULL
studies	NULL
of	NULL
CD4O0-mediated	NULL
growth	NULL
inhibition	NULL
and	NULL
apoptosis	NULL
in	NULL
transformed	NULL
cells	NULL
such	NULL
as	NULL
B	NULL
lymphoma	NULL
and	NULL
myeloma	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
31	NULL
)	NULL
.	NULL

One	NULL
explanation	NULL
for	NULL
CD40-mediated	NULL
apoptotic	NULL
signals	NULL
is	NULL
that	NULL
the	NULL
intracel-	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

CD40	NULL
ligation	NULL
inhibits	NULL
the	NULL
proliferation	NULL
of	NULL
human	NULL
melanoma	NULL
cells	NULL
via	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
.	NULL

LB39-Mel	NULL
cells	NULL
were	NULL
cultured	NULL
at	NULL
37°C/8	NULL
%	NULL
CO	NULL
;	NULL
for	NULL
72	NULL
h	NULL
when	NULL
photomicrographs	NULL
of	NULL
representative	NULL
cultures	NULL
were	NULL
taken	NULL
by	NULL
inverted	NULL
microscopy	NULL
(	NULL
magnification	NULL
,	NULL
X40	NULL
)	NULL
.	NULL

A	NULL
,	NULL
medium	NULL
alone	NULL
;	NULL
B	NULL
,	NULL
medium	NULL
plus	NULL
sCD40L	NULL
;	NULL
C	NULL
,	NULL
24	NULL
h	NULL
prestimulation	NULL
with	NULL
200	NULL
units/ml	NULL
recombinant	NULL
IFN	NULL
;	NULL
D	NULL
,	NULL
combined	NULL
IFN-y	NULL
priming	NULL
and	NULL
sCD4OL	NULL
stimulation	NULL
;	NULL
£	NULL
,	NULL
LB39-Mel	NULL
cells	NULL
with	NULL
or	NULL
without	NULL
IFN-y	NULL
(	NULL
200	NULL
units/ml	NULL
,	NULL
24	NULL
h	NULL
)	NULL
prestimulation	NULL
were	NULL
cocultured	NULL
on	NULL
monolayers	NULL
of	NULL
mitomycin	NULL
C-treated	NULL
CD40L	NULL
*	NULL
L-cells	NULL
or	NULL
untransfected	NULL
controls	NULL
for	NULL
48	NULL
h	NULL
at	NULL
37°C/8	NULL
%	NULL
CO	NULL
;	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
(	NULL
1	NULL
wCi/well	NULL
)	NULL
was	NULL
added	NULL
for	NULL
the	NULL
last	NULL
18	NULL
h	NULL
of	NULL
culture	NULL
after	NULL
which	NULL
thymidine	NULL
incorporation	NULL
was	NULL
measured	NULL
by	NULL
scintillation	NULL
spectroscopy	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
cpm	NULL
+	NULL
SD	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
from	NULL
quadruplicate	NULL
cultures	NULL
.	NULL

Background	NULL
proliferation	NULL
of	NULL
irradiated	NULL
L-cells	NULL
was	NULL
<	NULL
500	NULL
cpm	NULL
.	NULL

A	NULL
representative	NULL
experiment	NULL
of	NULL
four	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
LB39-Mel	NULL
or	NULL
MIRW	NULL
is	NULL
shown	NULL
.	NULL

F	NULL
,	NULL
FACS	NULL
analysis	NULL
of	NULL
terminal	NULL
deoxynucleotidyltransferase-mediated	NULL
dUTP-X	NULL
nick	NULL
end	NULL
labeling	NULL
staining	NULL
of	NULL
MIRW	NULL
cells	NULL
48	NULL
h	NULL
after	NULL
the	NULL
indicated	NULL
treatments	NULL
.	NULL

Cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
fixed	NULL
and	NULL
permeabilized	NULL
before	NULL
direct	NULL
labeling	NULL
with	NULL
FITC-dUTP	NULL
.	NULL

Comparable	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
the	NULL
melanoma	NULL
cell	NULL
line	NULL
LB39-Mel	NULL
stimulated	NULL
with	NULL
CD40L	NULL
L-cells	NULL
.	NULL

1293	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

EFFECTS	NULL
OF	NULL
CD40	NULL
LIGATION	NULL
ON	NULL
HUMAN	NULL
MALIGNANT	NULL
MELANOMA	NULL
lular	NULL
domain	NULL
of	NULL
CD40	NULL
shares	NULL
structural	NULL
homology	NULL
with	NULL
the	NULL
death	NULL
domains	NULL
of	NULL
p55TNFR	NULL
and	NULL
Fas	NULL
(	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
a	NULL
CD40	NULL
signaling	NULL
domain	NULL
involved	NULL
in	NULL
growth	NULL
inhibition	NULL
has	NULL
been	NULL
identified	NULL
recently	NULL
(	NULL
30	NULL
)	NULL
.	NULL

We	NULL
consider	NULL
it	NULL
unlikely	NULL
that	NULL
growth	NULL
inhibition	NULL
and	NULL
apoptosis	NULL
are	NULL
due	NULL
to	NULL
TNF-a	NULL
released	NULL
by	NULL
CD4O-triggered	NULL
MM	NULL
because	NULL
they	NULL
were	NULL
also	NULL
observed	NULL
in	NULL
TNF-a	NULL
@	NULL
-deficient	NULL
MIRW	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
neutralizing	NULL
sTNF-RI	NULL
.	NULL

Moreover	NULL
,	NULL
CD40	NULL
stimulation	NULL
did	NULL
not	NULL
alter	NULL
or	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
surface	NULL
Fas	NULL
or	NULL
FasL	NULL
on	NULL
MM	NULL
and	NULL
a	NULL
blocking	NULL
APO-1/Fas-immunoglobulin	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
any	NULL
CD40	NULL
triggered	NULL
changes	NULL
in	NULL
MM	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
CD40-induced	NULL
growth	NULL
inhibition	NULL
and	NULL
apoptosis	NULL
in	NULL
MM	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
TNF-a	NULL
or	NULL
Fas/FasL	NULL
expression	NULL
.	NULL

Finally	NULL
,	NULL
our	NULL
results	NULL
support	NULL
the	NULL
notion	NULL
that	NULL
the	NULL
loss	NULL
of	NULL
CD40	NULL
antigen	NULL
during	NULL
MM	NULL
progression	NULL
in	NULL
vivo	NULL
may	NULL
represent	NULL
yet	NULL
another	NULL
mechanism	NULL
of	NULL
tumor	NULL
escape	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
an	NULL
inhibition	NULL
of	NULL
CD40/CD4OL	NULL
interaction	NULL
by	NULL
anti-CD40L	NULL
mAb	NULL
prevented	NULL
tumor	NULL
rejection	NULL
of	NULL
CD40*	NULL
B16-F10	NULL
murine	NULL
MM	NULL
cells	NULL
(	NULL
9	NULL
,	NULL
46	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
latter	NULL
report	NULL
as	NULL
well	NULL
as	NULL
this	NULL
study	NULL
point	NULL
to	NULL
an	NULL
important	NULL
role	NULL
of	NULL
CD40/CD4O0L-mediated	NULL
signals	NULL
in	NULL
the	NULL
generation	NULL
and	NULL
perpetuation	NULL
of	NULL
specific	NULL
antitumor	NULL
immunity	NULL
in	NULL
CD40-positive	NULL
,	NULL
immunogenic	NULL
melanomas	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
Drs	NULL
.	NULL

Paul	NULL
Fisch	NULL
,	NULL
Catia	NULL
Traversari	NULL
,	NULL
Pascal	NULL
Chaux	NULL
,	NULL
and	NULL
Stefan	NULL
Martin	NULL
for	NULL
help	NULL
with	NULL
CTL	NULL
assays	NULL
and	NULL
stimulating	NULL
discussions	NULL
.	NULL

We	NULL
acknowledge	NULL
Brigitte	NULL
Mai	NULL
for	NULL
excellent	NULL
technical	NULL
assistance	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Stout	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
and	NULL
Suttles	NULL
,	NULL
J	NULL
.	NULL

The	NULL
many	NULL
roles	NULL
of	NULL
CD40	NULL
in	NULL
cell-mediated	NULL
inflammatory	NULL
responses	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
17	NULL
:	NULL
487-492	NULL
,	NULL
1996	NULL
.	NULL

2	NULL
.	NULL

Grewal	NULL
,	NULL
I.	NULL
S.	NULL
,	NULL
and	NULL
Flavell	NULL
,	NULL
R.	NULL
A.	NULL
CD40	NULL
and	NULL
CD154	NULL
in	NULL
cell-mediated	NULL
immunity	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
16	NULL
:	NULL
111-135	NULL
,	NULL
1998	NULL
.	NULL

3	NULL
.	NULL

Young	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Eliopoulos	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Gallagher	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
and	NULL
Dawson	NULL
,	NULL
C.	NULL
W.	NULL
CD40	NULL
and	NULL
epithelial	NULL
cells	NULL
:	NULL
across	NULL
the	NULL
great	NULL
divide	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
19	NULL
:	NULL
502-506	NULL
,	NULL
1998	NULL
.	NULL

4	NULL
.	NULL

Sad	NULL
,	NULL
S.	NULL
,	NULL
Krishnan	NULL
,	NULL
L.	NULL
,	NULL
Bleackley	NULL
,	NULL
R.	NULL
C.	NULL
,	NULL
Kiigi	NULL
,	NULL
D.	NULL
,	NULL
Hengartner	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Mosmann	NULL
,	NULL
T.	NULL
R.	NULL
Cytotoxicity	NULL
and	NULL
weak	NULL
CD40	NULL
ligand	NULL
expression	NULL
of	NULL
CD8+	NULL
type	NULL
2	NULL
cytotoxic	NULL
T	NULL
cells	NULL
restricts	NULL
their	NULL
potential	NULL
B	NULL
cell	NULL
helper	NULL
activity	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
27	NULL
:	NULL
914-922	NULL
,	NULL
1997	NULL
.	NULL

5	NULL
.	NULL

Bennett	NULL
,	NULL
S.	NULL
R.	NULL
M.	NULL
,	NULL
Carbone	NULL
,	NULL
F.	NULL
R.	NULL
,	NULL
Karamalis	NULL
,	NULL
F.	NULL
,	NULL
Flavell	NULL
,	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
J.	NULL
F.	NULL
A.	NULL
P.	NULL
,	NULL
and	NULL
Heath	NULL
,	NULL
W.	NULL
R.	NULL
Help	NULL
for	NULL
cytotoxic-T-cell	NULL
responses	NULL
is	NULL
mediated	NULL
by	NULL
CD40	NULL
signaling	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
393	NULL
:	NULL
478-480	NULL
,	NULL
1998	NULL
.	NULL

6	NULL
.	NULL

Schoenberger	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Toes	NULL
,	NULL
R.	NULL
E.	NULL
M.	NULL
,	NULL
van	NULL
der	NULL
Voort	NULL
,	NULL
E.	NULL
I.	NULL
H.	NULL
,	NULL
Offringa	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Melief	NULL
,	NULL
C.	NULL
J.	NULL
M.	NULL
T-cell	NULL
help	NULL
for	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
is	NULL
mediated	NULL
by	NULL
CD40-CD4O0L	NULL
interactions	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
393	NULL
:	NULL
480-483	NULL
,	NULL
1998	NULL
.	NULL

7	NULL
.	NULL

Mackey	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Barth	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
Noelle	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

The	NULL
role	NULL
of	NULL
CD40/CD154	NULL
interactions	NULL
in	NULL
the	NULL
priming	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
effector	NULL
function	NULL
of	NULL
helper	NULL
and	NULL
cytotoxic	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

,	NULL
63	NULL
:	NULL
418-428	NULL
,	NULL
1998	NULL
.	NULL

8	NULL
.	NULL

Borrow	NULL
,	NULL
P.	NULL
,	NULL
Tishon	NULL
,	NULL
A.	NULL
,	NULL
Lee	NULL
,	NULL
S.	NULL
,	NULL
Xu	NULL
,	NULL
J.	NULL
,	NULL
Grewal	NULL
,	NULL
I.	NULL
S.	NULL
,	NULL
Oldstone	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
and	NULL
Flavell	NULL
,	NULL
R.	NULL
A.	NULL
CD40L-deficient	NULL
mice	NULL
show	NULL
deficits	NULL
in	NULL
antiviral	NULL
immunity	NULL
and	NULL
have	NULL
an	NULL
impaired	NULL
memory	NULL
CD8+	NULL
CTL	NULL
response	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
183	NULL
;	NULL
2129-2142	NULL
,	NULL
1996	NULL
.	NULL

9	NULL
.	NULL

Mackey	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Gunn	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Ting	NULL
,	NULL
P.	NULL
P.	NULL
,	NULL
Kikutani	NULL
,	NULL
H.	NULL
,	NULL
Dranoff	NULL
,	NULL
G.	NULL
,	NULL
Noelle	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
and	NULL
Barth	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Jr	NULL
.	NULL

Protective	NULL
immunity	NULL
induced	NULL
by	NULL
tumor	NULL
vaccines	NULL
requires	NULL
interaction	NULL
between	NULL
CD40	NULL
and	NULL
its	NULL
ligand	NULL
,	NULL
CD154	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
57	NULL
:	NULL
2569-2574	NULL
,	NULL
1997	NULL
.	NULL

10	NULL
.	NULL

Bergamo	NULL
,	NULL
A.	NULL
,	NULL
Bataille	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Pellat-Deceunynck	NULL
,	NULL
C.	NULL
CD40	NULL
and	NULL
CD95	NULL
induce	NULL
cell	NULL
death	NULL
in	NULL
the	NULL
human	NULL
myeloma	NULL
cell	NULL
line	NULL
XG2	NULL
.	NULL

Br	NULL
.	NULL

J	NULL
.	NULL

Haematol	NULL
.	NULL

,	NULL
97	NULL
:	NULL
652-655	NULL
,	NULL
1997	NULL
.	NULL

11	NULL
.	NULL

Hess	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Engelmann	NULL
,	NULL
H.	NULL
A	NULL
novel	NULL
function	NULL
of	NULL
CD40	NULL
:	NULL
induction	NULL
of	NULL
cell	NULL
death	NULL
in	NULL
transformed	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
183	NULL
:	NULL
159-167	NULL
,	NULL
1996	NULL
.	NULL

12	NULL
.	NULL

Robbins	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
and	NULL
Kawakami	NULL
,	NULL
Y	NULL
.	NULL

Human	NULL
tumor	NULL
antigens	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
8	NULL
:	NULL
628-636	NULL
,	NULL
1996	NULL
.	NULL

13	NULL
.	NULL

Herin	NULL
,	NULL
M.	NULL
,	NULL
Lemoine	NULL
,	NULL
C.	NULL
,	NULL
Weynants	NULL
,	NULL
P.	NULL
,	NULL
Vessiere	NULL
,	NULL
F.	NULL
,	NULL
Van	NULL
Pel	NULL
,	NULL
A.	NULL
,	NULL
Knuth	NULL
,	NULL
A.	NULL
,	NULL
Devos	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Boon	NULL
,	NULL
T.	NULL
Production	NULL
of	NULL
stable	NULL
cytolytic	NULL
T-cell	NULL
clones	NULL
directed	NULL
against	NULL
autologous	NULL
human	NULL
melanoma	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
39	NULL
:	NULL
390-396	NULL
,	NULL
1987	NULL
.	NULL

14	NULL
.	NULL

Van	NULL
den	NULL
Eynde	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
and	NULL
van	NULL
der	NULL
Bruggen	NULL
,	NULL
P.	NULL
T	NULL
cell	NULL
defined	NULL
tumor	NULL
antigens	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
9	NULL
:	NULL
684-693	NULL
,	NULL
1997	NULL
.	NULL

15	NULL
.	NULL

Mattei	NULL
,	NULL
S.	NULL
,	NULL
Colombo	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Melani	NULL
,	NULL
C.	NULL
,	NULL
Silvani	NULL
,	NULL
A.	NULL
,	NULL
Parmiani	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Herlyn	NULL
,	NULL
M.	NULL
Expression	NULL
of	NULL
cytokine/growth	NULL
factors	NULL
and	NULL
their	NULL
receptors	NULL
in	NULL
human	NULL
melanoma	NULL
and	NULL
melanocytes	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
56	NULL
:	NULL
853-857	NULL
,	NULL
1994	NULL
.	NULL

16	NULL
.	NULL

May	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Ghosch	NULL
,	NULL
S.	NULL
Signal	NULL
transduction	NULL
through	NULL
NF-KB	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
19	NULL
;	NULL
80-89	NULL
,	NULL
1998	NULL
.	NULL

17.	NULL
van	NULL
den	NULL
Oord	NULL
,	NULL
J.	NULL
J.	NULL
,	NULL
Maes	NULL
,	NULL
A.	NULL
,	NULL
Stas	NULL
,	NULL
M.	NULL
,	NULL
Nuyts	NULL
,	NULL
J.	NULL
,	NULL
Battocchio	NULL
,	NULL
S.	NULL
,	NULL
Kasran	NULL
,	NULL
A.	NULL
,	NULL
Garmyn	NULL
,	NULL
M.	NULL
,	NULL
De	NULL
Wever	NULL
,	NULL
I.	NULL
,	NULL
and	NULL
De	NULL
Wolf-Peeters	NULL
,	NULL
C.	NULL
CD40	NULL
is	NULL
a	NULL
prognostic	NULL
marker	NULL
in	NULL
primary	NULL
cutancous	NULL
malignant	NULL
melanoma	NULL
.	NULL

Am	NULL
.	NULL

J	NULL
.	NULL

Pathol	NULL
.	NULL

,	NULL
49	NULL
;	NULL
1953-1961	NULL
,	NULL
1996	NULL
.	NULL

18	NULL
.	NULL

Thomas	NULL
,	NULL
W.	NULL
D.	NULL
,	NULL
Smith	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Si	NULL
,	NULL
Z.	NULL
,	NULL
and	NULL
Hersey	NULL
,	NULL
P.	NULL
Expression	NULL
of	NULL
the	NULL
costimulatory	NULL
molecule	NULL
CD40	NULL
on	NULL
melanoma	NULL
cells	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
68	NULL
:	NULL
795-801	NULL
,	NULL
1996	NULL
.	NULL

19	NULL
.	NULL

Hollenbaugh	NULL
,	NULL
D.	NULL
,	NULL
Mischel-Petty	NULL
,	NULL
N.	NULL
,	NULL
Edwards	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
Simon	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Denfeld	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
Kiener	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Aruffo	NULL
,	NULL
A	NULL
.	NULL

Expression	NULL
of	NULL
functional	NULL
CD40	NULL
by	NULL
vascular	NULL
endothelial	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
182	NULL
:	NULL
33-40	NULL
,	NULL
1995	NULL
.	NULL

20	NULL
.	NULL

Salter	NULL
,	NULL
R.	NULL
D.	NULL
,	NULL
Howell	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
and	NULL
Cresswell	NULL
,	NULL
P.	NULL
Genes	NULL
regulating	NULL
HLA	NULL
class	NULL
I	NULL
antigen	NULL
expression	NULL
in	NULL
T-B	NULL
lymphoblast	NULL
hybrids	NULL
.	NULL

Immunogenetics	NULL
,	NULL
27	NULL
:	NULL
235-246	NULL
,	NULL
1985	NULL
.	NULL

21.	NULL
van	NULL
den	NULL
Eynde	NULL
,	NULL
B.	NULL
,	NULL
Hainaut	NULL
,	NULL
P.	NULL
,	NULL
Herin	NULL
,	NULL
M.	NULL
,	NULL
Knuth	NULL
,	NULL
A.	NULL
,	NULL
Lemone	NULL
,	NULL
C.	NULL
,	NULL
Weynants	NULL
,	NULL
P.	NULL
,	NULL
van	NULL
den	NULL
Bruggen	NULL
,	NULL
P.	NULL
,	NULL
Fauchet	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Boon	NULL
,	NULL
T.	NULL
Presence	NULL
on	NULL
a	NULL
human	NULL
melanoma	NULL
of	NULL
multiple	NULL
antigens	NULL
recognized	NULL
by	NULL
autologous	NULL
CTL	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
44	NULL
:	NULL
634-640	NULL
,	NULL
1989	NULL
.	NULL

22	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
Sester	NULL
,	NULL
M.	NULL
,	NULL
Burgert	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
Activation	NULL
of	NULL
Transcription	NULL
factor	NULL
NF-kB	NULL
by	NULL
the	NULL
Adenovirus	NULL
E3/19K	NULL
protein	NULL
requires	NULL
its	NULL
ER	NULL
retention	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
132	NULL
:	NULL
511-522	NULL
,	NULL
1996	NULL
.	NULL

23.	NULL
van	NULL
Muijen	NULL
,	NULL
G.	NULL
N.	NULL
,	NULL
Danen	NULL
,	NULL
E.	NULL
H.	NULL
,	NULL
Veerkamp	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Ruiter	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Lesley	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
van	NULL
den	NULL
Heuvel	NULL
,	NULL
L.	NULL
P.	NULL
Glycoconjugate	NULL
profile	NULL
and	NULL
CD44	NULL
expression	NULL
in	NULL
human	NULL
melanoma	NULL
cell	NULL
lines	NULL
with	NULL
different	NULL
metastatic	NULL
capacity	NULL
.	NULL

Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
,	NULL
67	NULL
:	NULL
241-248	NULL
,	NULL
1995	NULL
.	NULL

24	NULL
.	NULL

Stamenkovic	NULL
,	NULL
I.	NULL
,	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
and	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

A	NULL
B-lymphocyte	NULL
activation	NULL
molecule	NULL
related	NULL
to	NULL
the	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
and	NULL
induced	NULL
by	NULL
cytokines	NULL
in	NULL
carcinomas	NULL
.	NULL

EMBO	NULL
J.	NULL
,	NULL
8	NULL
:	NULL
1403-1410	NULL
,	NULL
1989	NULL
.	NULL

25	NULL
.	NULL

Colombo	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Maccalli	NULL
,	NULL
C.	NULL
,	NULL
Mattei	NULL
,	NULL
S.	NULL
,	NULL
Melani	NULL
,	NULL
C.	NULL
,	NULL
Radrizzani	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Parmiani	NULL
,	NULL
G.	NULL
Expression	NULL
of	NULL
cytokine	NULL
genes	NULL
,	NULL
including	NULL
IL-6	NULL
,	NULL
in	NULL
human	NULL
malignant	NULL
melanoma	NULL
cell	NULL
lines	NULL
.	NULL

Melanoma	NULL
Res	NULL
.	NULL

,	NULL
2	NULL
:	NULL
181-189	NULL
,	NULL
1992	NULL
.	NULL

26	NULL
.	NULL

Berberich	NULL
,	NULL
I.	NULL
,	NULL
Shu	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
and	NULL
Clark	NULL
,	NULL
E.	NULL
A.	NULL
Cross-linking	NULL
CD40	NULL
on	NULL
B	NULL
cells	NULL
rapidly	NULL
activates	NULL
nuclear	NULL
factor-kB	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
153	NULL
:	NULL
4357-4366	NULL
,	NULL
1994	NULL
.	NULL

27	NULL
.	NULL

Hess	NULL
,	NULL
S.	NULL
,	NULL
Rensing-Ehl	NULL
,	NULL
A.	NULL
,	NULL
Schwabe	NULL
,	NULL
R.	NULL
,	NULL
Bufler	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Engelmann	NULL
,	NULL
H.	NULL
CD40	NULL
function	NULL
in	NULL
non-hematopoietic	NULL
cells	NULL
.	NULL

Nuclear	NULL
factor	NULL
kB	NULL
mobilization	NULL
and	NULL
induction	NULL
of	NULL
IL-6	NULL
production	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
155	NULL
;	NULL
4588-4595	NULL
,	NULL
1995	NULL
.	NULL

28	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
Machleidt	NULL
,	NULL
T.	NULL
,	NULL
Alkalay	NULL
,	NULL
I.	NULL
,	NULL
Kronke	NULL
,	NULL
M.	NULL
,	NULL
Ben	NULL
,	NULL
N.	NULL
Y.	NULL
,	NULL
and	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Rapid	NULL
proteolytic	NULL
degradation	NULL
of	NULL
IxBa	NULL
induced	NULL
by	NULL
stimulation	NULL
of	NULL
cell	NULL
with	NULL
phorbol	NULL
ester	NULL
,	NULL
cytokines	NULL
and	NULL
liposaccharides	NULL
is	NULL
a	NULL
necessary	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factor	NULL
NF-kB	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

,	NULL
365	NULL
:	NULL
182-184	NULL
,	NULL
1993	NULL
.	NULL

29	NULL
.	NULL

Boon	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
van	NULL
der	NULL
Bruggen	NULL
,	NULL
P.	NULL
Human	NULL
tumor	NULL
antigens	NULL
recognized	NULL
by	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
183	NULL
:	NULL
725-729	NULL
,	NULL
1996	NULL
.	NULL

30	NULL
.	NULL

Goldstein	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
and	NULL
Watts	NULL
,	NULL
T.	NULL
H.	NULL
Identification	NULL
of	NULL
distinct	NULL
domains	NULL
in	NULL
CD40	NULL
involved	NULL
in	NULL
B7-1	NULL
induction	NULL
or	NULL
growth	NULL
inhibition	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
157	NULL
:	NULL
2837-2843	NULL
,	NULL
1996	NULL
.	NULL

31	NULL
.	NULL

Funakoshi	NULL
,	NULL
S.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Beckwith	NULL
,	NULL
M.	NULL
,	NULL
Conley	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Tsarfaty	NULL
,	NULL
G.	NULL
,	NULL
Tsarfaty	NULL
,	NULL
I.	NULL
,	NULL
Armitage	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Fanslow	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Spriggs	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
and	NULL
Murphy	NULL
,	NULL
W.	NULL
J.	NULL
Inhibition	NULL
of	NULL
human	NULL
B-cell	NULL
lymphoma	NULL
growth	NULL
by	NULL
CD40	NULL
stimulation	NULL
.	NULL

Blood	NULL
,	NULL
83	NULL
:	NULL
2787-2794	NULL
,	NULL
1994	NULL
.	NULL

32	NULL
.	NULL

Schwartz	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
and	NULL
Osborne	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Programmed	NULL
cell	NULL
death	NULL
,	NULL
apoptosis	NULL
and	NULL
killer	NULL
genes	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
,	NULL
14	NULL
:	NULL
582-590	NULL
,	NULL
1993	NULL
.	NULL

33	NULL
.	NULL

Armstrong	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Botella	NULL
,	NULL
R.	NULL
,	NULL
Galloway	NULL
,	NULL
T.	NULL
H.	NULL
,	NULL
Murray	NULL
,	NULL
N.	NULL
,	NULL
Kramp	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Song	NULL
,	NULL
I.	NULL
S.	NULL
,	NULL
and	NULL
Ansel	NULL
,	NULL
J.	NULL
C.	NULL
Antitumor	NULL
effects	NULL
of	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
production	NULL
by	NULL
melanoma	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
56	NULL
:	NULL
2191-2198	NULL
,	NULL
1996	NULL
.	NULL

34	NULL
.	NULL

Dranoff	NULL
,	NULL
G.	NULL
,	NULL
Jaffee	NULL
,	NULL
E.	NULL
,	NULL
Lazenby	NULL
,	NULL
A.	NULL
,	NULL
Golumbek	NULL
,	NULL
P.	NULL
,	NULL
Levitsky	NULL
,	NULL
H.	NULL
,	NULL
Brose	NULL
,	NULL
K.	NULL
,	NULL
Jackson	NULL
,	NULL
V.	NULL
,	NULL
Hamada	NULL
,	NULL
H.	NULL
,	NULL
Pardoll	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Mulligan	NULL
,	NULL
R.	NULL
C.	NULL
Vaccination	NULL
with	NULL
irradiated	NULL
tumor	NULL
cells	NULL
engineered	NULL
to	NULL
secrete	NULL
murine	NULL
granulocyte	NULL
colony-stimulating	NULL
factor	NULL
stimulates	NULL
potent	NULL
,	NULL
specific	NULL
,	NULL
and	NULL
long-lasting	NULL
antitumor	NULL
immunity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
90	NULL
:	NULL
3539-3543	NULL
,	NULL
1993	NULL
.	NULL

35	NULL
.	NULL

Armstrong	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Murray	NULL
,	NULL
N.	NULL
,	NULL
Kennedy	NULL
,	NULL
M.	NULL
,	NULL
Koppula	NULL
,	NULL
S.	NULL
V.	NULL
,	NULL
Tara	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Ansel	NULL
,	NULL
J.	NULL
C.	NULL
Melanoma-derived	NULL
interleukin	NULL
6	NULL
inhibits	NULL
in	NULL
vivo	NULL
melanoma	NULL
growth	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

,	NULL
102	NULL
:	NULL
278-284	NULL
,	NULL
1994	NULL
.	NULL

36	NULL
.	NULL

Baggiolini	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Clark-Lewis	NULL
,	NULL
I.	NULL
Interleukin-8	NULL
,	NULL
a	NULL
chemotactic	NULL
and	NULL
inflammatory	NULL
cytokine	NULL
.	NULL

FEBS	NULL
Lett	NULL
.	NULL

,	NULL
307	NULL
:	NULL
97-101	NULL
,	NULL
1992	NULL
.	NULL

37	NULL
.	NULL

Beutler	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Cerami	NULL
,	NULL
A	NULL
.	NULL

The	NULL
biology	NULL
of	NULL
cachectin/TNF-a	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
7	NULL
:	NULL
625-655	NULL
,	NULL
1989	NULL
.	NULL

38	NULL
.	NULL

Garbe	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Krasagakis	NULL
,	NULL
K.	NULL
Effects	NULL
of	NULL
interferons	NULL
and	NULL
cytokines	NULL
on	NULL
melanoma	NULL
cells	NULL
.	NULL

J	NULL
.	NULL

Invest	NULL
.	NULL

Dermatol	NULL
.	NULL

,	NULL
100	NULL
:	NULL
239-244	NULL
,	NULL
1993	NULL
.	NULL

39	NULL
.	NULL

Rivoltini	NULL
,	NULL
L.	NULL
,	NULL
Barracchini	NULL
,	NULL
K.	NULL
C.	NULL
,	NULL
Viggiano	NULL
,	NULL
V.	NULL
,	NULL
Kawakami	NULL
,	NULL
Y.	NULL
,	NULL
Smith	NULL
,	NULL
A.	NULL
,	NULL
Mixon	NULL
,	NULL
A.	NULL
,	NULL
Restifo	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
Topalain	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Rosenberg	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
and	NULL
Marincola	NULL
,	NULL
F.	NULL
M.	NULL
Quantitative	NULL
correlation	NULL
between	NULL
HLA	NULL
class	NULL
I	NULL
allele	NULL
expression	NULL
and	NULL
recognition	NULL
of	NULL
melanoma	NULL
cells	NULL
by	NULL
antigen-specific	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

,	NULL
55	NULL
:	NULL
3149-3157	NULL
,	NULL
1995	NULL
.	NULL

40	NULL
.	NULL

Cayabyab	NULL
,	NULL
M.	NULL
,	NULL
Phillips	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Lanier	NULL
,	NULL
L.	NULL
L.	NULL
CD40	NULL
preferentially	NULL
costimulates	NULL
activation	NULL
of	NULL
CD4+	NULL
T	NULL
lymphocytes	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
152	NULL
;	NULL
1523-1531	NULL
,	NULL
1994	NULL
.	NULL

41	NULL
.	NULL

Hermann	NULL
,	NULL
P.	NULL
,	NULL
Van-Kooten	NULL
,	NULL
C.	NULL
,	NULL
Gaillard	NULL
,	NULL
C.	NULL
,	NULL
Banchereau	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Blanchard	NULL
,	NULL
D.	NULL
CD40	NULL
ligand-positive	NULL
CD8+	NULL
T	NULL
cell	NULL
clones	NULL
allow	NULL
B	NULL
cell	NULL
growth	NULL
and	NULL
differentiation	NULL
.	NULL

Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
25	NULL
:	NULL
2972-2977	NULL
,	NULL
1995	NULL
.	NULL

42	NULL
.	NULL

Becker	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Dummer	NULL
,	NULL
R.	NULL
,	NULL
Hartmann	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Burg	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Schmidt	NULL
,	NULL
R.	NULL
E.	NULL
Shedding	NULL
of	NULL
ICAM-1	NULL
from	NULL
human	NULL
melanoma	NULL
cell	NULL
lines	NULL
induced	NULL
by	NULL
IFN-y	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-a	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
147	NULL
;	NULL
4398-4401	NULL
,	NULL
1991	NULL
.	NULL

43	NULL
.	NULL

Riinger	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Klein	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Becker	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Brécker	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

The	NULL
role	NULL
of	NULL
genetic	NULL
instability	NULL
,	NULL
adhesion	NULL
,	NULL
cell	NULL
motility	NULL
,	NULL
and	NULL
immune	NULL
escape	NULL
mechanisms	NULL
in	NULL
melanoma	NULL
progression	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Oncol	NULL
.	NULL

,	NULL
6	NULL
:	NULL
188-196	NULL
,	NULL
1994	NULL
.	NULL

44	NULL
.	NULL

Tartaglia	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Ayres	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Wong	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
and	NULL
Goeddel	NULL
,	NULL
D.	NULL
V.	NULL
A	NULL
novel	NULL
domain	NULL
within	NULL
the	NULL
55	NULL
kd	NULL
TNF	NULL
receptor	NULL
signals	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
,	NULL
74	NULL
:	NULL
845-853	NULL
,	NULL
1993	NULL
.	NULL

45	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Nagata	NULL
,	NULL
S.	NULL
A	NULL
novel	NULL
protein	NULL
domain	NULL
required	NULL
for	NULL
apoptosis	NULL
.	NULL

Mutational	NULL
analysis	NULL
of	NULL
human	NULL
Fas	NULL
antigen	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
268	NULL
:	NULL
10932-10937	NULL
,	NULL
1993	NULL
.	NULL

46	NULL
.	NULL

Bohm	NULL
,	NULL
W.	NULL
,	NULL
Thoma	NULL
,	NULL
S.	NULL
,	NULL
Leithauser	NULL
,	NULL
F.	NULL
,	NULL
Moller	NULL
,	NULL
P.	NULL
,	NULL
Schirmbeck	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Reimann	NULL
,	NULL
J.	NULL
T-cell	NULL
mediated	NULL
,	NULL
IFN-y-facilitated	NULL
rejection	NULL
of	NULL
murine	NULL
B16	NULL
melanomas	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
161	NULL
:	NULL
897-908	NULL
,	NULL
1998	NULL
.	NULL

1294	NULL
Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

AAGR	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
Cancer	NULL
Research	NULL
The	NULL
Journal	NULL
of	NULL
Cancer	NULL
Research	NULL
(	NULL
1916-1930	NULL
)	NULL
|	NULL
The	NULL
American	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1931-1940	NULL
)	NULL
Stimulation	NULL
of	NULL
CD40	NULL
on	NULL
Immunogenic	NULL
Human	NULL
Malignant	NULL
Melanomas	NULL
Augments	NULL
Their	NULL
Cytotoxic	NULL
T	NULL
Lymphocyte-mediated	NULL
Lysis	NULL
and	NULL
Induces	NULL
Apoptosis	NULL
Achim	NULL
von	NULL
Leoprechting	NULL
,	NULL
Pierre	NULL
van	NULL
der	NULL
Bruggen	NULL
,	NULL
Heike	NULL
L.	NULL
Pahl	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Cancer	NULL
Res	NULL
287-1294	NULL
.	NULL

Updated	NULL
version	NULL
Access	NULL
the	NULL
most	NULL
recent	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/6/1287	NULL
Cited	NULL
articles	NULL
Citing	NULL
articles	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
articles	NULL
,	NULL
17	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/6/1	NULL
287	NULL
.full	NULL
#	NULL
ref-list-1	NULL
This	NULL
article	NULL
has	NULL
been	NULL
cited	NULL
by	NULL
18	NULL
HighWire-hosted	NULL
articles	NULL
.	NULL

Access	NULL
the	NULL
articles	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/6/1	NULL
287	NULL
.full	NULL
#	NULL
related-urls	NULL
E-mail	NULL
alerts	NULL
Reprints	NULL
and	NULL
Subscriptions	NULL
Permissions	NULL
Sign	NULL
up	NULL
to	NULL
receive	NULL
free	NULL
email-alerts	NULL
related	NULL
to	NULL
this	NULL
article	NULL
or	NULL
journal	NULL
.	NULL

To	NULL
order	NULL
reprints	NULL
of	NULL
this	NULL
article	NULL
or	NULL
to	NULL
subscribe	NULL
to	NULL
the	NULL
journal	NULL
,	NULL
contact	NULL
the	NULL
AACR	NULL
Publications	NULL
Department	NULL
at	NULL
pubs	NULL
@	NULL
aacr.org	NULL
.	NULL

To	NULL
request	NULL
permission	NULL
to	NULL
re-use	NULL
all	NULL
or	NULL
part	NULL
of	NULL
this	NULL
article	NULL
,	NULL
use	NULL
this	NULL
link	NULL
http	NULL
:	NULL
//cancerres.aacrjournals.org/content/59/6/1287	NULL
.	NULL

Click	NULL
on	NULL
``	NULL
Request	NULL
Permissions	NULL
``	NULL
which	NULL
will	NULL
take	NULL
you	NULL
to	NULL
the	NULL
Copyright	NULL
Clearance	NULL
Center	NULL
's	NULL
(	NULL
CCC	NULL
)	NULL
Rightslink	NULL
site	NULL
.	NULL

Downloaded	NULL
from	NULL
cancerres.aacrjournals.org	NULL
on	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

©	NULL
1999	NULL
American	NULL
Association	NULL
for	NULL
Cancer	NULL
Research	NULL
.	NULL

